Great Basin Scientific (GBSN) S-1 20 Jan 15 IPO registration Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014
Document And Entity Information [Abstract]
Document Type	S-1
Amendment Flag	FALSE
Document Period End Date	30-Sep-14
Trading Symbol	GBSN
Entity Registrant Name	Great Basin Scientific, Inc.
Entity Central Index Key	1512138
Entity Filer Category	Smaller Reporting Company

CONDENSED_BALANCE_SHEETS

CONDENSED BALANCE SHEETS (USD $)	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Current assets:
Cash	$676,471	$1,211,423	$1,143,009
Accounts receivable, net	233,426	184,415	102,976
Inventory	381,952	320,239	94,080
Prepaid and other current assets	895,160	94,421	22,857
Subscription receivable			3,288,333
Total current assets	2,187,009	1,810,498	4,651,255
Intangible assets, net	245,896	334,025	206,704
Property and equipment, net	3,529,265	3,703,582	1,731,439
Total assets	5,962,170	5,848,105	6,589,398
Current liabilities:
Accounts payable	1,695,497	874,119	724,246
Accrued expenses	858,412	815,814	492,254
Current portion of notes payable	48,586	44,601
Notes payable-related party, net of discount of $83,333	416,667
Current portion of capital lease obligations	959,403	506,506	32,543
Total current liabilities	3,978,565	2,241,040	1,249,043
Notes payable, net of current portion	18,732	55,730
Capital lease obligations, net of current portion	2,435,625	2,042,359	122,593
Derivative liability	13,900,400	0
Total liabilities	20,333,322	4,339,129	1,371,636
Commitments and contingencies (see NOTE 10 LEGAL PROCEEDINGS)
Stockholders' deficit:
Common stock	162	116	116
Additional paid-in capital	11,481,055	9,733,342	9,622,251
Accumulated deficit	-65,507,780	-42,276,878	-32,715,598
Total stockholders' deficit	-54,026,563	-32,543,420	-23,093,231
Total liabilities, convertible preferred stock and stockholders' deficit	5,962,170	5,848,105	6,589,398
Series A Convertible Preferred Stock
Convertible preferred stock:
Convertible preferred stock	17,366,539	18,846,539	18,846,539
Series B Convertible Preferred Stock
Convertible preferred stock:
Convertible preferred stock	9,464,454	9,464,454	9,464,454
Series C Convertible Preferred Stock
Convertible preferred stock:
Convertible preferred stock	4,040,585	3,674,335
Series C-1 Convertible Preferred Stock
Convertible preferred stock:
Convertible preferred stock	2,067,068	2,067,068
Series D Convertible Preferred Stock
Convertible preferred stock:
Convertible preferred stock	6,716,765
Pro Forma
Current assets:
Cash	676,471
Accounts receivable, net	233,426
Inventory	381,952
Prepaid and other current assets	895,160
Total current assets	2,187,009
Intangible assets, net	245,896
Property and equipment, net	3,529,265
Total assets	5,962,170
Current liabilities:
Accounts payable	1,695,497
Accrued expenses	858,412
Current portion of notes payable	48,586
Notes payable-related party, net of discount of $83,333	416,667
Current portion of capital lease obligations	959,403
Total current liabilities	3,978,565
Notes payable, net of current portion	18,732
Capital lease obligations, net of current portion	2,435,625
Derivative liability	13,900,400
Total liabilities	20,333,322
Commitments and contingencies (see NOTE 10 LEGAL PROCEEDINGS)
Stockholders' deficit:
Common stock	3,779
Additional paid-in capital	51,132,849
Accumulated deficit	-65,507,780
Total stockholders' deficit	-14,371,152
Total liabilities, convertible preferred stock and stockholders' deficit	$5,962,170

CONDENSED_BALANCE_SHEETS_Paren

CONDENSED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Allowance for doubtful accounts receivable, current	$5,482	$5,482	$0
Notes payable - related party, discount	$83,333
Common stock, par value	$0.00	$0.00	$0.00
Common stock, shares authorized	1,800,000,000	375,000,000	700,000,000
Common stock, shares issued	161,760	115,510	115,510
Common stock, shares outstanding	161,760	115,510	115,510
Convertible Preferred Stock
Preferred stock, par value		$0.00	$0.00
Preferred stock, shares authorized		535,000,000	225,000,000
Series A Convertible Preferred Stock | Convertible Preferred Stock
Preferred stock, par value	$0.00	$0.00	$0.00
Preferred stock, shares authorized	119,987,898	125,000,000	125,000,000
Preferred stock, shares issued	107,881,171	117,131,171	117,131,171
Preferred stock, shares outstanding	107,881,171	117,131,171	117,131,171
Series B Convertible Preferred Stock | Convertible Preferred Stock
Preferred stock, par value	$0.00	$0.00	$0.00
Preferred stock, shares authorized	59,465,350	100,000,000	100,000,000
Preferred stock, shares issued	59,465,350	59,465,350	59,465,350
Preferred stock, shares outstanding	59,465,350	59,465,350	59,465,350
Series C Convertible Preferred Stock | Convertible Preferred Stock
Preferred stock, par value	$0.00	$0.00	$0.00
Preferred stock, shares authorized	165,877,435	210,000,000	210,000,000
Preferred stock, shares issued	165,877,435	150,989,224	0
Preferred stock, shares outstanding	165,877,435	150,989,224	0
Series C-1 Convertible Preferred Stock | Convertible Preferred Stock
Preferred stock, par value	$0.00	$0.00	$0.00
Preferred stock, shares authorized	84,027,175	100,000,000	100,000,000
Preferred stock, shares issued	84,027,175	84,027,175	0
Preferred stock, shares outstanding	84,027,175	84,027,175	0
Series D Convertible Preferred Stock | Convertible Preferred Stock
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	325,000,000	0
Preferred stock, shares issued	306,091,710	0
Preferred stock, shares outstanding	306,091,710	0

CONDENSED_STATEMENTS_OF_OPERAT

CONDENSED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Income Statement [Abstract]
Revenues	$409,390	$223,470	$1,160,971	$464,861	$760,646	$38,667
Cost of sales	942,334	660,695	2,761,153	1,078,610	2,185,992	733,702
Gross loss	-532,944	-437,225	-1,600,182	-613,749	-1,425,346	-695,035
Operating expenses:
Research and development	1,424,877	792,690	3,265,149	2,678,912	3,345,693	3,706,193
Selling and marketing	479,499	725,984	1,646,782	2,066,479	2,618,901	1,164,775
General and administrative	597,795	384,664	2,004,080	1,257,109	1,866,875	1,075,387
(Gain) loss on sale of assets		6,504	-8,166	22,767	22,768	28,278
Total operating expenses	2,502,171	1,909,842	6,907,845	6,025,267	7,854,237	5,974,633
Loss from operations	-3,035,115	-2,347,067	-8,508,027	-6,639,016	-9,279,583	-6,669,668
Other income (expense):
Interest expense	-314,450	-82,239	-819,235	-114,065	-284,323	-603,763
Interest income	619	889	2,057	2,945	3,876	3,501
Change in fair value of derivative liability	-13,900,400		-13,900,400
Total other income (expense)	-14,214,231	-81,350	-14,717,578	-111,120	-280,447	-600,262
Loss before provision for income taxes	-17,249,346	-2,428,417	-23,225,605	-6,750,136	-9,560,030	-7,269,930
Provision for income taxes	822		-5,297		-1,250	-100
Net loss	-17,248,524	-2,428,417	-23,230,902	-6,750,136	-9,561,280	-7,270,030
Less: Cumulative preferred stock dividends (undeclared)					-2,533,470	-966,687
Net loss attributable to common stockholders					($12,094,750)	($8,236,717)
Net loss per common share-basic and diluted	($117.59)	($21.02)	($184.35)	($58.44)	($104.71)	($71.31)
Weighted average common shares-basic and diluted	146,678	115,510	126,014	115,510	115,510	115,510

STATEMENT_OF_STOCKHOLDERS_DEFI

STATEMENT OF STOCKHOLDERS' DEFICIT (USD $)	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Beginning balance, value at Dec. 31, 2011	($15,934,292)	$116	$9,511,160	($25,445,568)
Beginning balance, shares at Dec. 31, 2011		115,510
Employee stock option expense	111,091		111,091
Net loss for the year	-7,270,030			-7,270,030
Ending balance, value at Dec. 31, 2012	-23,093,231	116	9,622,251	-32,715,598
Ending balance, Shares at Dec. 31, 2012		115,510
Employee stock option expense	111,091		111,091
Net loss for the year	-9,561,280			-9,561,280
Ending balance, value at Dec. 31, 2013	($32,543,420)	$116	$9,733,342	($42,276,878)
Ending balance, Shares at Dec. 31, 2013		115,510

CONDENSED_STATEMENTS_OF_CASH_F

CONDENSED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:
Net loss	($23,230,902)	($6,750,136)	($9,561,280)	($7,270,030)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	855,484	549,629	854,950	315,655
Change in fair value measurement	13,900,400
(Gain) loss on sale of assets	-8,166	22,767	22,768	28,278
Interest converted to preferred stock	13,129		139,403	593,203
Employee stock compensation	242,696	83,317	111,091	111,091
Warrant issuance and modifications	25,063
Debt discount amortization	16,667
Asset disposal	11,124
Changes in operating assets and liabilities:
Increase in accounts receivable, net	-49,011	-46,400	-81,439	-102,976
Increase in inventory	-61,713	-95,040	-226,159	-94,080
Increase in prepaid and other assets	-269,459	-29,765	-71,564	-17,411
Increase in accounts payable	360,882	135,029	149,873	172,521
Increase in accrued liabilities	42,598	415,182	323,560	34,999
Net cash used in operating activities	-8,151,208	-5,715,417	-8,338,797	-6,228,750
Cash flows from investing activities:
Acquisition of property and equipment	-222,584	-774,540	-595,819	-145,540
Acquisition of intangible asset		-200,000	-225,000	-25,000
Construction of equipment	-479,196	-1,774,341	-2,181,563	-1,197,302
Proceeds from sale of assets	35,000	63,000	63,000	106,500
Proceeds from sale leaseback	1,500,000		2,500,000
Net cash provided by (used in) investing activities	833,220	-2,685,881	-439,382	-1,261,342
Cash flows from financing activities:
Proceeds from issuance of convertible notes payable	100,000	4,577,688	4,577,688	8,256,668
Proceeds from issuance of convertible notes payable-related party	300,000
Proceeds from issuance of preferred stock	6,569,886		1,160,000	170,000
Proceeds from issuance of notes payable-related party	890,000
Proceeds from subscriptions receivable		3,288,333	3,288,333
Principal payments of capital leases	-653,837	-23,677	-144,071	-16,919
Principal payments of notes payable	-390,000	-24,995	-35,357
Principal payments of notes payable-related party	-33,013
Net cash provided by financing activities	6,783,036	7,817,349	8,846,593	8,409,749
Net increase (decrease) in cash	-534,952	-583,949	68,414	919,657
Cash, beginning of the period	1,211,423	1,143,009	1,143,009	223,352
Cash, end of the period	676,471	559,060	1,211,423	1,143,009
Supplemental disclosures of cash flow information:
Interest paid	775,666	10,021	144,920	10,560
Income taxes paid	6,447
Supplemental schedule of non-cash investing and financing activities:
Conversion of preferred stock to common stock	1,480,000
Issuance of preferred stock as debt discount	100,000
Conversion of note payable to preferred stock	400,000		4,442,000	12,114,776
Preferred stock issued for subscription receivable				3,288,333
Assets acquired through capital leases	807,272		1,293,205	122,382
Initial public offering costs incurred but unpaid	531,280
Property and equipment included in accounts payable	$70,784

Description_of_Business

Description of Business	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Accounting Policies [Abstract]
Description of Business	NOTE 1    DESCRIPTION OF BUSINESS	NOTE 1    DESCRIPTION OF BUSINESS
	Great Basin Scientific, Inc. (the “Company”) (d.b.a., Great Basin Corporation) is a Delaware corporation headquartered in Salt Lake City, Utah. The Company was originally incorporated as Diagnostic Micro Arrays, Inc., a Nevada corporation, on June 27, 2003. The Company changed its name to Great Basin Scientific, Inc. on April 19, 2006. On August 12, 2008, the Company took steps to change its corporate domicile from Nevada to Delaware by forming Great Basin Scientific, Inc., a Delaware corporation, and on August 29, 2008, Great Basin Scientific, Inc., a Nevada corporation, was merged with and into Great Basin Scientific, Inc., a Delaware corporation, wherein the Delaware corporation was the sole surviving entity.	Great Basin Scientific, Inc. (the “Company”) (d.b.a., Great Basin Corporation) is a Delaware corporation headquartered in Salt Lake City, Utah. The Company was originally incorporated as Diagnostic Micro Arrays, Inc., a Nevada corporation, on June 27, 2003. The Company changed its name to Great Basin Scientific, Inc. on April 19, 2006. On August 12, 2008, the Company took steps to change its corporate domicile from Nevada to Delaware by forming Great Basin Scientific, Inc., a Delaware corporation and on August 29, 2008, Great Basin Scientific, Inc., a Nevada corporation, was merged with and into Great Basin Scientific, Inc., a Delaware corporation, wherein the Delaware corporation was the sole surviving entity.
	The Company is a molecular diagnostics company that develops and manufactures test kits and analyzers for a patented, proprietary low-cost, easy-to-use molecular diagnostic system for single pathogen tests. The Company sells its test kits to customers throughout the world for use in the Company’s analyzers. Our system utilizes a sample-in result-out format, enabling simple, rapid and cost-effective analysis of multiple pathogens from a single clinical sample. The Company’s technology processes up to 64 distinct targets in a single assay for more answers with results in 90 minutes or less. It is a fully automated process with few hands-on steps that allows on-demand testing instead of the traditional batching of tests that delay results. The Company’s simple-to-use system allows smaller hospitals that traditionally could not afford more expensive, advanced molecular diagnostics systems to modernize their laboratory testing and provide better patient care at an affordable cost.	The Company is a molecular diagnostics company that develops and manufactures test kits and analyzers for a patented, proprietary low-cost, easy-to-use molecular diagnostic system for single pathogen tests. The Company sells its test kits to customers throughout the world for use in the Company’s analyzers. Our system utilizes a sample-in result-out format, enabling simple, rapid and cost-effective analysis of multiple pathogens from a single clinical sample. The Company’s technology processes up to 64 distinct targets in a single assay for more answers with results in 90 minutes or less. It is a fully automated process with few hands-on steps that allows on- demand testing instead of the traditional batching of tests that delay results. The Company’s simple-to-use system allows smaller hospitals that traditionally could not afford more expensive, advanced molecular diagnostics systems to modernize their laboratory testing and provide better patient care at an affordable cost.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Basis of Presentation	Basis of Presentation
	These condensed unaudited financial statements have been prepared to reflect the financial position, results of operations and cash flows of the Company as of September 30, 2014 and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information. The accompanying condensed financial statements and notes are unaudited. In management’s opinion, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of September 30, 2014 and its results of operations and cash flows for the nine months ended September 30, 2014 and 2013. The results for the nine months ended September 30, 2014 are not necessarily indicative of the results expected for the full fiscal year or any other interim period.	These financial statements have been prepared to reflect the financial position, results of operations and cash flows of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
	Loss per Common Share	Use of Estimates
	Basic loss per share (“EPS”) is computed by dividing net loss (the numerator) by the weighted average number of common shares outstanding for the period (the denominator). Diluted EPS is computed by dividing net loss by the weighted average number of common shares and potential common shares outstanding (if dilutive) during each period. Potential common shares include convertible preferred stock, stock options and warrants. The number of potential common shares outstanding is computed using the treasury stock method.	The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Such estimates include the sales return reserve, accounts receivable and inventory reserves, intangible assets and other long lived assets, legal and regulatory contingencies, income taxes and others. These estimates and assumptions are based on management’s best estimates and judgments. Actual amounts and results could differ from those estimates.
	As the Company has incurred losses for the nine months ended September 30, 2014 and 2013, the potentially dilutive shares are anti-dilutive and are thus not added into the loss per share calculations. As of September 30, 2014 and 2013, there were 8,141,418 and 2,082,111 potentially dilutive shares, respectively.	Cash and Cash Equivalents
	Reverse Stock Split	The Company considers highly liquid investments with insignificant interest rate risk and original maturities to the Company of three months or less to be cash equivalents. Cash equivalents consist primarily of interest and non-interest bearing bank accounts held in checking, savings and money market accounts. These assets are generally available on a daily or weekly basis and are highly liquid in nature. If the balances are greater than $250,000, the Company does not have FDIC coverage on the entire amount of bank deposits.
	On September 5, 2014, the Company effected a reverse stock split of the Company’s common stock whereby each two hundred shares of common stock was replaced with one share of common stock (with no fractional shares issued). The par value and authorized shares of the common stock were not adjusted as a result of the reverse stock split. All common share, options, warrants and per share amounts for all periods presented in these financial statements have been adjusted retroactively to reflect the reverse stock split. The convertible preferred stock was not included in the reverse stock split and the outstanding amounts have not been adjusted. However, the conversion ratio was adjusted as a result of the reverse stock split such that upon conversion, each two hundred shares of preferred stock will be converted into one share of common stock.	Accounts Receivable
	New Accounting Pronouncements	Accounts receivable are generated from the sale of single use diagnostic test cartridges to end users in the United States and to a network of distributors outside the United States. These accounts receivable are recorded at the invoiced amount, net of allowances for doubtful amounts. The Company routinely reviews outstanding accounts
	From time to time, new accounting pronouncements are issued by the FASB that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption.	receivable balances for estimated uncollectible accounts and establishes or adjusts the allowances for doubtful accounts receivable using the specific identification method and records a reserve for amounts not expected to be fully recovered. Actual balances are not applied against the reserve until substantially all collection efforts have been exhausted. The Company does not have customer acceptance provisions, but it does provide its customers a limited right of return for defective diagnostic test cartridges.
	In May 2014, the Financial Accounting Standards Board issued accounting guidance on revenue recognition. The amended guidance will enhance the comparability of revenue recognition practices and will be applied to all contracts with customers. Improved disclosures related to the nature, amount, timing, and uncertainty of revenue that is recognized are requirements under the amended guidance. This guidance will be effective for fiscal 2017 and will be required to be applied retrospectively. We are currently assessing the impact that this guidance will have on our financial statements at this time.	The Company accrues an estimated amount for sales returns and allowances related to defective product at the time of sale based on its ability to estimate sales returns and allowances using current and historical information. The reserve for sales returns and allowances is included as a reduction to revenue and accounts receivable, net.
		The balance of accounts receivable at December 31, 2013 and 2012, net of an allowance for doubtful accounts of $5,482 and $0, was $184,415 and $102,976, respectively.
		Inventories
		Inventories are stated at the lower of cost or market with cost determined according to the average cost method. Manufactured inventory consists of raw material, direct labor and manufacturing overhead cost components. The Company reviews the components of its inventory on a regular basis for excess and obsolete inventory and makes appropriate adjustments when necessary. Inventories consisted of the following at December 31, 2013 and 2012:
			December 31,
			2013		2012
		Raw materials	$	278,947	$	80,909
		Work-in-process		39,192		13,171
		Finished goods		2,100		-
		Total inventories	$	320,239	$	94,080
		Property and Equipment
		Property and equipment is recorded at cost and depreciated over the estimated useful lives of the assets (which range from three to ten years) using the straight-line method. Amortization of leasehold improvements is computed on the straight-line method over the shorter of the lease term or estimated useful lives of the assets. The analyzers that the Company manufactures and retains title over are placed with customers and are recorded in property and equipment under “Analyzers.” The materials used for the manufacture of the analyzers are recorded in property and equipment under “Construction in progress.” Major renewals and betterments are capitalized and depreciated over their estimated useful lives while minor expenditures for maintenance and minor repairs are charged to operations as incurred.
		The Company classifies assets to be sold as assets held for sale when (i) Company management has approved and commits to a plan to sell the asset, (ii) the asset is available for immediate sale in its present condition and is ready for sale, (iii) an active program to locate a buyer and other actions required to sell the asset have been initiated, (iv) the sale of the asset is probable, (v) the asset is being actively marketed for sale at a price that is reasonable in relation to its current fair value, and (vi) it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn. Assets classified as held for sale are recorded at the lower of the carrying amount or fair value less the cost to sell and are a component of prepaid and other current assets in the balance sheets. The Company did not have any assets classified as held for sale as of December 31, 2013 and 2012.
		Intangible Assets
		The Company records its intangible assets at cost which consist of two licensing and royalty agreements for certain intellectual property rights used in the development and manufacture of our products. These intangible assets are being amortized over a period of seven years from the date that the technology licenses became effective. As of December 31, 2013 and 2012, intangible assets totaled $600,000 and $375,000 valued at cost, less accumulated amortization of $265,975 and $168,296, respectively. The Company estimates that approximately $118,409 will be amortized per year. The Company recorded amortization associated with these agreements of $97,680 and $60,563 for the years ended December 31, 2013 and 2012, respectively.
		Impairment of Long Lived Assets
		Long-lived tangible assets, including property and equipment, and definite-lived intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. The Company regularly evaluates whether events or circumstances have occurred that indicate possible impairment and relies on a number of factors, including expected future operating results, business plans, economic projections, and anticipated future cash flows. The Company uses an estimate of the future undiscounted net cash flows and comparisons to like-kind assets, as appropriate, of the related asset over the remaining life in measuring whether the assets are recoverable. Measurement of the amount of impairment, if any, is based upon the difference between the asset’s carrying value and estimated fair value. Fair value is determined through various valuation techniques, including cost-based, market and income approaches as considered necessary.
		Fair Value of Financial Instruments
		The Company measures at fair value certain of its financial and non-financial assets and liabilities by using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price, based on the highest and best use of the asset or liability. The levels of the fair value hierarchy are:
		Level 1—Quoted market prices in active markets for identical assets or liabilities;
		Level 2—Significant other observable inputs (e.g. quoted prices for similar items in active markets, quoted prices for identical or similar items in markets that are not active, inputs other than quoted prices that are observable, such as interest rate and yield curves, and market-corroborated inputs); and
		Level 3—Unobservable inputs in which there is little or no market data, which require the reporting unit to develop its own assumptions.
		Revenue Recognition
		The Company derives its product revenue from the sale of single use diagnostic test cartridges sold through our dedicated sales force, except in the European Union where the Company sells through a network of distributors. Product revenue is recognized when all four of the following criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery of the products has occurred; (3) the selling price of the product is fixed or determinable; and (4) collectability of that price is reasonably assured. Change in title to the product and recognition of revenue from sales of diagnostic test cartridges occurs at the time of shipment. Shipping and handling fees and related freight costs and supplies for test kits are billed to customers. Additional costs associated with shipping products to customers as well as the 2.3% excise tax on the sale of medical devices in the United States are included as a component of cost of goods sold.
		Research and Development Costs
		Research and development costs are charged to operations as incurred. Research and development costs include, among other things, salaries and wages for research scientists and staff (including stock-based compensation), materials and supplies used in the development of new products, developing and validating the manufacturing process, costs for clinical trials, and costs for research and development facilities and equipment.
		Stock Based Compensation
		The Company has accounted for stock-based compensation under the provisions of Financial Accounting Standards Board Accounting Standards Codification (“FASB ASC”) 718, “Compensation – Stock Compensation”. This standard requires the Company to record an expense associated with the fair value of stock- based compensation over the requisite service period. The Company uses the Black-Scholes option valuation model to calculate the value of options at the date of grant. Option pricing models require the input of highly subjective assumptions, including the estimated fair value of the Company’s common stock on the date of grant, the expected term of the stock option, and the expected price volatility of the Company’s common stock over the period equal to the expected term of the grant. Changes in these assumptions can materially affect the fair value estimate. The Company estimates forfeitures at the date of grant and revises the estimates, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
		Financial Instruments and Concentration of Credit Risk
		The Company’s financial instruments include cash and cash equivalents, accounts receivable, and accounts payable. The carrying amount of cash and cash equivalents, accounts receivable, and accounts payable approximate fair value because of their immediate or short-term maturities.
		All of the Company’s accounts receivable result from sales in the normal course of business to its customers primarily throughout the United States. The Company attempts to limit its credit risk by performing credit evaluations of new customers and maintaining adequate allowances for potential credit losses. As of December 31, 2013, 25% of the accounts receivable balance resulted from one customer. As of December 31, 2012, 78% of the accounts receivable balances resulted from three customers. Historically, the Company has not experienced significant credit losses on such receivables. Allowances for bad debt in the amount of $5,482 were recorded against accounts receivable for the year ended December 31, 2013. There was no bad debt for the year ended December 31, 2012. The Company cannot ensure that such losses will not be realized in the future.
		The Company’s customers are primarily hospitals and health clinics. For the year ended December 31, 2013, 23% of revenues resulted from two customers who each accounted for more than 10% of revenues. For the year ended December 31, 2012, 58% of revenues resulted from three customers who each accounted for more than 10% of revenues.
		Income Taxes
		The Company accounts for income taxes under FASB ASC 740, “Income Taxes”. Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are
		expected to reverse. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is “more likely than not” that some component or all of the benefits of deferred tax assets will not be realized.
		The tax effects from an uncertain tax position can be recognized in the financial statements only if the position is more likely than not of being sustained if the position were to be challenged by a taxing authority. The Company has examined the tax positions taken in its tax returns and determined that there are no uncertain tax positions. As a result, the Company has recorded no uncertain tax liabilities in its balance sheet.
		Loss per Common Share
		Basic loss per share (“EPS”) is computed by dividing net loss, less cumulative preferred stock dividends for the period, including undeclared or unpaid cumulative dividends (the numerator) by the weighted average number of common shares outstanding for the period (the denominator). Diluted EPS is computed by dividing net loss by the weighted average number of common shares and potential common shares outstanding (if dilutive) during each period. Potential common shares include convertible preferred stock, stock options and warrants. The number of potential common shares outstanding is computed using the treasury stock method.
		As the Company has incurred losses for the years ended December 31, 2013 and 2012, the potentially dilutive shares are anti-dilutive and are thus not added into the loss per share calculations. As of December 31, 2013 and 2012, there were 2,459,343 and 1,179,265 potentially dilutive shares, respectively.
		New Accounting Pronouncements
		From time to time, new accounting pronouncements are issued by the FASB that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption.
		In May 2014, the Financial Accounting Standards Board issued accounting guidance on revenue recognition. The amended guidance will enhance the comparability of revenue recognition practices and will be applied to all contracts with customers. Improved disclosures related to the nature, amount, timing, and uncertainty of revenue that is recognized are requirements under the amended guidance. This guidance will be effective for fiscal 2017 and will be required to be applied retrospectively. We are currently assessing the impact that this guidance will have on our financial statements at this time.
		Reverse Stock Split
		On September 5, 2014, the Company effected a reverse stock split of the Company’s common stock whereby each two hundred shares of stock was replaced with one share of stock (with no fractional shares issued). The par value and the authorized shares of the common and convertible preferred stock were not adjusted as a result of the reverse stock split. All common share and per share amounts for all periods presented in these financial statements have been adjusted retroactively to reflect the reverse stock split.

Going_Concern

Going Concern	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Text Block [Abstract]
Going Concern	NOTE 3    GOING CONCERN	NOTE 3    GOING CONCERN
	The Company’s condensed unaudited financial statements have been prepared on a going concern basis which contemplates the realization of assets and the liquidation of liabilities in the ordinary course of business. The Company has incurred substantial losses from operations causing negative working capital and negative operating cash flows, which raise substantial doubt about the Company’s ability to continue as a going concern. The Company sustained a net loss for the nine months ended September 30, 2014 of $23,230,902 and a net loss for the year ended December 31, 2013 of $9,561,280, and has an accumulated deficit of $65,507,780 as of September 30, 2014.	The Company’s financial statements have been prepared on a going concern basis which contemplates the realization of assets and the liquidation of liabilities in the ordinary course of business. The Company has incurred substantial losses from operations causing negative working capital and negative operating cash flows,
	The Company intends to develop its products and expand its customer base, but does not have sufficient realized revenues or operating cash flows in order to finance these activities internally. As a result, the Company intends to seek financing in order to fund its working capital and development needs.	which raise substantial doubt about the Company’s ability to continue as a going concern. The Company sustained a net loss for the year ended December 31, 2013 of $9,561,280 and a net loss for the year ended December 31, 2012 of $7,270,030, and has an accumulated deficit of $42,276,878 as of December 31, 2013.
	The Company has been able to meet its short-term needs through private placements of convertible preferred securities, convertible notes and the sale and leaseback of analyzers used to report test results. The Company will continue to seek funding through the issuance of additional equity securities, debt financing, the sale and leaseback of analyzers, or a combination of these items. Any proceeds received from these items could provide the needed funds for continued operations and development programs. The Company can provide no assurance that it will be able to obtain sufficient additional financing that it needs to alleviate doubt about its ability to continue as a going concern. If the Company is able to obtain sufficient additional financing proceeds, the Company cannot be certain that this additional financing will be available on acceptable terms, if at all. To the extent the Company raises additional funds by issuing equity securities, the Company’s stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact the Company’s ability to conduct business. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. If the Company is unable to obtain additional financings, the impact on the Company’s operations will be material and adverse.	The Company intends to develop its products and expand its customer base, but does not have sufficient realized revenues or operating cash flows in order to finance these activities internally. As a result, the Company intends to seek financing in order to fund its working capital and development needs.
		The Company has been able to meet its short-term needs through private placements of convertible preferred securities and the sale and leaseback of analyzers used to report test results. The Company will continue to seek funding through the issuance of additional equity securities, debt financing, the sale and leaseback of analyzers, or a combination of these items. Any proceeds received from these items could provide the needed funds for continued operations and development programs. The Company can provide no assurance that it will be able to obtain sufficient additional financing that it needs to alleviate doubt about its ability to continue as a going concern. If the Company is able to obtain sufficient additional financing proceeds, the Company cannot be certain that this additional financing will be available on acceptable terms, if at all. To the extent the Company raises additional funds by issuing equity securities, the Company’s stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact the Company’s ability to conduct business. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. If the Company is unable to obtain additional financings, the impact on the Company’s operations will be material and adverse.

Property_And_Equipment

Property And Equipment	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]
Property And Equipment	NOTE 4    PROPERTY AND EQUIPMENT
	Property and equipment consisted of the following at December 31, 2013 and December 31, 2012:
		December 31,
		2013			2012
	Construction in progress	$	308,411		$	212,189
	Analyzers		1,421,293			918,940
	Computers and office equipment		244,454			219,190
	Machinery and equipment		910,643			400,154
	Leasehold improvements		366,945			326,640
	Furniture and fixtures		11,730			6,414
	Equipment under capital lease		1,462,122			188,918
			4,725,598			2,272,445
	Less: accumulated depreciation and amortization		(1,022,016	)		(541,006	)
	Total Property and equipment, net	$	3,703,582		$	1,731,439
	The total expense for depreciation of fixed assets and amortization of leasehold improvements was $757,270 and $255,092 for the years ended December 31, 2013 and 2012, respectively.

Accrued_Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]
Accrued Expenses	NOTE 5    ACCRUED EXPENSES
	Accrued liabilities consisted of the following as of December 31, 2013 and 2012:
		December 31,
		2013		2012
	Accrued payroll	$	564,740	$	441,646
	Royalties		105,319		-
	Accrued interest		39,808		-
	Accrued property tax		99,707		50,508
	Other		6,240		100
	Total accrued liabilities	$	815,814	$	492,254

Commitments

Commitments	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]
Commitments	NOTE 11    COMMITMENTS	NOTE 6    LEASE COMMITMENTS
	The Company entered into a second agreement in April 2014 for the sale-leaseback of molecular diagnostic analyzers. The agreement provided for the sale of 75 molecular diagnostic analyzers for a purchase price of $1,500,000, which are being leased back for thirty-six monthly payments of $64,665. At the end of the lease term, the lease shall automatically renew for twelve additional months at the current monthly rate unless the Company gives written notice 150 days prior to the end of the lease. If timely notice is given the Company shall have the opportunity to: 1) repurchase the analyzers for a negotiated purchase price, not to exceed forty percent of their original cost; or 2) terminate the lease, return the property and enter into a new lease with new property that replaces the property of the old lease. Both the Company and the lessor shall have the right to reject any terms of option 1 or 2 and if rejected, the 12 month extension shall apply. The agreement has a rewrite clause wherein the leasing company agrees to use its commercially best efforts to rewrite the lease agreement at more favorable terms when the Company raises sufficient capital to cover current and future expenses for a minimum of 12 months. The Company’s obligations under the lease agreement are secured by a $500,000 letter of credit. The Letter of Credit was issued by a bank at the behest of a non-profit foundation and Spring Forth Investments LLC both of which are related parties through Mr. David Spafford, a director of the Company. The Company is obligated to reimburse the non-profit foundation and Spring Forth Investments LLC for any draws made under the Letter of Credit. The lease agreement is also secured by personal guarantees from Mr. Ryan Ashton, the Chief Executive Officer of the Company, and Mr. Spafford. The lease is accounted for as a capital lease sale-leaseback transaction in accordance with ASC 840, “Leases”.	Capital Leases
	The Company entered into a second Financial Advisory Agency Agreement with Rona Capital LLC effective in June 2014, wherein Rona Capital will provide the Company with financial advisory services related to the Company’s ongoing financing activities. The Company will pay Rona Capital LLC $15,000 per month and an additional cash amount of $100,000 that will be paid upon the closing of the initial public offering. The Company has also agreed to issue warrants to Rona Capital to purchase shares of the Company’s common stock such that Rona Capital shall own 1% of the Company’s outstanding equity that vest upon continued service to the Company as a consultant or employee. These terms were fulfilled subsequent to the initial public offering.	The Company leases certain machinery and equipment under various capital lease agreements ranging from three to five years. In addition, the Company entered into a lease agreement in October 2013 for the sale-leaseback of molecular diagnostic analyzers. The agreement provided for the sale of 125 molecular diagnostic analyzers for a purchase price of $2,500,000, which are being leased back for thirty-six monthly payments of $74,875. At the end of the lease term, the lease shall automatically renew for twelve additional months at the current monthly rate unless the Company gives written notice 150 days prior to the end of the lease. If timely notice is given the Company shall have the opportunity to: 1) repurchase the analyzers for a negotiated purchase price, not to exceed forty percent of their original cost; or 2) terminate the lease, return the property and enter into a new lease with new property that replaces the property of the old lease. Both the Company and the lessor shall have the right to reject any terms of option 1 or 2 and if rejected, the 12 month extension shall apply. The Company’s obligations under the lease agreement are secured by letters of credit by a related party and by personal guarantees from
		Mr. Ryan Ashton, the Chief Executive Officer of the Company, and Mr. David Spafford, a director of the Company (See Note 11 RELATED PARTY TRANSACTIONS). The lease is accounted for as a capital lease sale-leaseback transaction in accordance with ASC 840, “Leases”.
		Annual future maturities of capital leases for the next five years are as follows:
		Years ended December 31,
		2014	$	506,506
		2015		613,433
		2016		723,938
		2017		704,988
		Total capital lease commitments		2,548,865
		Less: current portion of capital leases		(506,506	)
		Long term portion of capital leases	$	2,042,359
		Operating leases
		The Company leases office and manufacturing buildings as well as certain office equipment such as copiers and printers under operating lease agreements that expire at various dates.
		Amounts charged to expense under operating leases were $284,941 and $174,249 for the years ended December 31, 2013 and 2012, respectively.
		Operating lease commitments for the next five years are as follows:
		Years ended December 31,
		2014	$	287,657
		2015		97,522
		2016		2,397
		2017		715
		Total operating lease commitments	$	388,291

Long_Term_Debt

Long Term Debt	9 Months Ended							12 Months Ended
	Sep. 30, 2014							Dec. 31, 2013
Debt Disclosure [Abstract]
Long Term Debt	NOTE 4    NOTES PAYABLE							NOTE 7    LONG TERM DEBT
	The Company purchased certain machinery and equipment under two note payable agreements which consist of the following as of September 30, 2014 and December 31, 2013:							The Company purchased certain machinery and equipment under two note payable agreements which consist of the following as of December 31, 2013 and 2012:
		September 30,			December 31,				December 31,
		2014			2013				2013			2012
	Note payable, 15.2% interest, monthly payments of $ 1,328, due February 6, 2016, secured by equipment.	$	20,194		$	29,259		Note payable, 15.2% interest, monthly payments of $1,328, due February 6, 2016, secured by equipment.	$	29,259		$	-
	Note payable, 10.0% interest, monthly payments of $ 3,161, due January 1, 2016, secured by equipment.		47,124			71,072		Note payable, 10.0% interest, monthly payments of $3,161, due January 1, 2016, secured by equipment.		71,072			-
	Total notes payable		67,318			100,331		Total notes payable		100,331			-
	Less: current portion of notes payable		(48,586	)		(44,601	)	Less: current portion of notes payable		(44,601	)		-
	Long term portion of notes payable	$	18,732		$	55,730		Long term portion of notes payable	$	55,730		$	-

Common_and_Preferred_Stock

Common and Preferred Stock	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Equity [Abstract]
Common and Preferred Stock	NOTE 6    PREFERRED STOCK	NOTE 8    COMMON AND PREFERRED STOCK
	During the nine months ended September 30, 2014 the Company issued 14,888,211 shares of Series C preferred stock for cash in the amount of $366,250 or $0.0246 per share. The shares of Series C preferred stock are convertible into shares of common stock at a ratio of 200:1, at the option of the holder at any time after issuance. The series C preferred stock will be automatically converted upon a qualified initial public offering, or upon the election of a majority of the outstanding shares.	Common Stock
	During the nine months ended September 30, 2014 the Company sold 285,566,560 shares of Series D preferred stock units for gross proceeds in the amount of $7,139,164 or $0.025 per unit and after deducting offering costs and expenses, the Company received $6,203,636 in net proceeds. The preferred stock units are separable into 285,566,560 shares of Series D preferred stock, 1,427,832 Class A warrants to purchase a share of common stock at $4.92 and 1,427,832 Class B warrants to purchase a share of common stock at $0.20. The shares of Series D preferred stock are convertible into shares of common stock at a ratio of 200:1, at the option of the holder at any time after issuance. The Series D preferred stock will be automatically converted upon a qualified initial public offering, or upon the election of a majority of the outstanding shares. In conjunction with the offering an additional 7,200,000, 466,436 and 251,216 of Series D preferred stock warrants, Class A warrants and Class B warrants, respectively, were granted as part of the offering costs.	The Company had 700,000,000 and 375,000,000 shares of common stock authorized at a par value of $0.001 per share as of December 31, 2013 and 2012, respectively. As of December 31, 2013 and 2012 there were
	In July 2014, the Company converted notes payable in the amount of $400,000 plus $13,129 in accrued interest into 16,525,121 Series D preferred stock units at a conversion price of $0.025 per share. These units consist of 16,525,121 shares of Series D preferred stock, 82,625 Class A warrants to purchase a share of common stock at $4.92 and 82,625 Class B warrants to purchase a share of common stock at $0.20. The shares of Series D preferred stock are convertible into shares of common stock at a ratio of 200:1, at the option of the holder at any time after issuance. The conversion of the notes was pursuant to the terms of the notes that upon a qualified equity financing of at least $5 million the notes would be converted into shares of the equity securities at the price per share at which the equity securities were issued in the qualified equity financing. The sale of the Series D preferred stock units through July 2014 met this threshold and triggered the conversion.	115,510 shares of common stock issued and outstanding. There were no issuances of common stock during 2013 or 2012.
	In July 2014, as additional consideration for the issuance of a the Spring Forth Note (See NOTE 5 NOTES PAYABLE—RELATED PARTY) the Company issued 4,000,000 Series D preferred stock units (which are separable into 4,000,000 shares of Series D preferred stock, 20,000 Class A warrants to purchase a share of common stock at $4.92 and 20,000 Class B warrants to purchase a share of common stock at $0.20) at a value of $100,000 or $0.025 per unit.	Preferred Stock
	In July 2014, Spring Forth Investments exercised its conversion option and converted 9,250,000 shares of Series A preferred stock valued at $1,480,000 or $0.16 per share into 46,250 shares of common stock.	The Company had 535,000,000 and 225,000,000 shares of preferred stock authorized at a par value of $0.001 per share as of December 31, 2013 and 2012, respectively. The preferred stock is divided into series by which the Company was authorized to issue 125,000,000 shares of Series A preferred stock as of December 31, 2013 and 2012; 100,000,000 shares of Series B preferred stock as of December 31, 2013 and 2012; and 210,000,000 shares of Series C and 100,000,000 shares of Series C-1 as of December 31, 2013.
	The Series C and Series D preferred stock have a conversion price adjustment provision that in the event the Company sells shares of any additional stock, subject to certain exceptions, at a price per share less than the original issue price of the respective series preferred stock, the conversion price shall be adjusted to a price equal to the price paid per share for such additional stock. These conversion price adjustment provisions, and other relevant features of the preferred stock, were analyzed in accordance with the provisions of FASB ASC 815, “Derivatives and Hedging”. The Company evaluated the conversion price adjustment provision embedded in the preferred stock and other relevant features and determined, in accordance with the provisions of the referenced accounting guidance, that such conversion option or other relevant features do not meet the criteria requiring bifurcation as a derivative liability of these instruments. The characteristics of the common stock that is issuable upon a holder’s exercise of the conversion option embedded in the convertible preferred stock are deemed to be clearly and closely related to the characteristics of the preferred shares. Further, the Company determined the other relevant features of the preferred stock are clearly and closely related to the equity host and do not qualify for derivative accounting.	As of December 31, 2013, there were 117,131,171 shares of Series A preferred stock outstanding; 59,465,350 shares of Series B preferred stock outstanding; 150,989,224 shares of Series C preferred stock outstanding; and 84,027,175 shares of Series C-1 preferred stock outstanding. As of December 31, 2012 there were 117,131,171 shares of Series A preferred stock outstanding and 59,465,350 shares of Series B preferred stock outstanding.
	In July 2014, the Company filed a sixth amended and restated Certificate of Incorporation authorizing a modification to the number of authorized shares of common stock and Series D preferred stock. The number of common shares authorized was amended to 1,800,000,000 shares and the number of Series D preferred shares authorized was amended to 325,000,000 shares. In addition Hitachi Chemical Co., Ltd. was given the right to elect one director upon certain requirements and any amendment that would affect this right would require Hitachi’s consent.	All series of preferred stock are convertible into shares of common stock at a ratio of 200:1, at the option of the holder at any time after issuance. The preferred stock will be automatically converted upon a qualified initial public offering, or upon the election of a majority of the outstanding shares of each respective series. The conversion rate is subject to adjustment from time to time for certain dilutive events.
		Each share of preferred stock is entitled to receive cumulative dividends as may be declared at the per annum rate of $0.0128 per share prior to and in preference to the payment of any dividends on the common stock. As of December 31, 2013 and 2012, preferred stock dividends in arrears were $5,108,338 and $2,574,869, respectively.
		The approval of a majority of the Series A preferred stock, Series B preferred stock and Series C preferred stock, voting together as a single class, is required to: modify the rights, preferences or privilege of any class of the preferred stock; create a new class of stock with preferences senior to or on parity with the Series A preferred stock, Series B preferred stock, Series C preferred stock or Series C-1 preferred stock: change the authorized number of shares of any class of preferred stock; take any action that would result in certain liquidity events; declare or pay any dividend; redeem or repurchase issued and outstanding common stock (with certain limited exceptions), increase the shares issuable under the Company’s stock option plan; or change the number of authorized directors of the Company.
		In the event of a liquidation, the holders of Series C preferred stock and Series C-1 preferred stock will each be entitled to receive a distribution equal to $0.0492 per share (subject to adjustments for stock splits, dividends, recapitalizations and the like), plus any declared but unpaid dividends on such shares, before any distribution is made to the holders of common stock, Series B preferred stock or Series A preferred stock.
		In the event of such liquidity events and after payment has been made to holders of Series C preferred stock and Series C-1 preferred stock pursuant to the liquidation preferences described above, the holders of Series B Preferred Stock will each be entitled to receive a distribution equal to $0.32 per share (subject to adjustments for stock splits, dividends, recapitalizations and the like), plus any declared but unpaid dividends on such shares, before any distribution is made to the holders of common stock or Series A preferred stock.
		In the event of such liquidity events and after payment has been made to holders of Series C preferred stock, Series C-1 preferred stock and Series B preferred stock pursuant to the liquidation preferences described above, the holders of Series A preferred stock will each be entitled to receive a distribution equal to $0.32 per share (subject to adjustments for stock splits, dividends, recapitalizations and the like), plus any declared but unpaid dividends on such shares, before any distribution is made to the holders of common stock.
		A sale, merger, reorganization, liquidation, dissolution or winding up of the Company may, in certain circumstances, result in a change in control and be deemed to be a liquidation event that triggers the liquidation preferences associated with the outstanding shares of preferred stock. Because a change in control could occur and not be solely within the control of the Company, all convertible preferred stock has been deemed to be contingently redeemable and classified outside of permanent equity in the accompanying balance sheets. However, because the timing of any such redemption is uncertain, the Company will not accrete the carrying value of the convertible preferred stock to its liquidation preference value until it becomes probable that redemption will occur.
		In December 2012 the Company issued 41,886,599 shares of Series A preferred stock pursuant to the exercise of convertible notes in the amount of $6,150,000 plus interest of $551,856 for a total conversion price of $6,701,856 or $0.16 per share. The Company also issued 38,632,015 shares of Series B preferred stock for cash in the amount of $170,000 net of offering costs and pursuant to the exercise of convertible notes in the amount of $5,856,667 plus interest of $149,456 for a total issuance price of $6,176,123 or $0.16 per share.
		In December 2012 the Company issued 20,833,334 shares of Series B preferred stock pursuant to a subscription receivable in the amount of $3,288,333 or $0.16 per share. The subscription receivable for these shares was subsequently paid with cash in January and February 2013. As the full subscription amount was received in cash prior to the publication of the financial statements, the subscription amount was classified as an asset as of December 31, 2012 as permitted.
		During the year ended December 31, 2013 the Company issued 150,989,224 shares of Series C preferred stock for cash in the amount of $1,160,000 net of offering costs and pursuant to the exercise of convertible notes in the amount $2,442,000 plus interest of $72,338 for a total issuance price of $3,674,338 or $0.0246 per share. The Company also issued 84,027,174 shares of Series C-1 preferred stock pursuant to the exercise of a convertible note in the amount of $2,000,000 plus interest of $67,068 for a total conversion price of $2,067,068 or $0.0246 per share.
		The conversion price adjustment provision of all the preferred stock series dictates that in the event the Company sells shares of any additional stock, subject to certain exceptions, at a price per share less than the original issue price of the respective series preferred stock, the conversion price shall be adjusted to a price equal to the price paid per share for such additional stock. These conversion price adjustment provisions, and other relevant features of the preferred stock, were analyzed in accordance with the provisions of FASB ASC 815, “Derivatives and Hedging”. The Company evaluated the conversion price adjustment provision embedded in the preferred stock and other relevant features and determined, in accordance with the provisions of the referenced accounting guidance, that such conversion option or other relevant features do not meet the criteria requiring bifurcation as a derivative liability of these instruments. The characteristics of the common stock that is issuable upon a holder’s exercise of the conversion option embedded in the convertible preferred stock are deemed to be clearly and closely related to the characteristics of the preferred shares. Further, the Company determined the other relevant features of the preferred stock are clearly and closely related to the equity host and do not qualify for derivative accounting.

Warrants

Warrants	9 Months Ended								12 Months Ended
	Sep. 30, 2014								Dec. 31, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Warrants	NOTE 7    WARRANTS								NOTE 9    WARRANTS
	As of September 30, 2014, there were 4,178,782, 2,231,727 and 7,200,000 fully vested warrants outstanding to purchase shares of common stock, shares of Series A preferred stock and shares of Series D preferred stock, respectively. During the nine months ended September 30, 2014, a total of 3,904,362 warrants to purchase shares of common stock and 7,200,000 warrants to purchase shares of Series D preferred stock were granted.								As of December 31, 2013 and 2012, there were 274,420 and 174,420 warrants to purchase shares of common stock outstanding and fully vested, respectively. As of December 31, 2013 and 2012 there were 2,231,727 warrants to purchase shares of Series A preferred stock. During the year ended December 31, 2013 warrants totaling 100,000 for shares of common stock were granted. There were no warrants granted during the year ended December 31, 2012.
	Of the total warrants to purchase common stock granted during the nine months ended September 30, 2014; 2,855,664 Class A and Class B warrants to purchase common stock were issued as part of the sale for cash of the Series D preferred stock units (see NOTE 6 PREFERRED STOCK) that have an exercise price between $0.20 and $4.92 and expire between April 2021 and July 2021.								The 100,000 warrants were granted on November 14, 2013 and were issued as compensation to two related parties in conjunction with providing their personal guarantee of the leaseback agreement on our analyzers (see NOTE 6 LEASE COMMITMENTS and NOTE 11 RELATED PARTY TRANSACTIONS). The warrants have an exercise price of $2.00 and expire seven years from the date of grant. These transactions are accounted for by the Company under the provisions of FASB ASC 505 which require the Company to record an expense associated with the fair value of stock-based payments. The Company uses the Black-Scholes option valuation model to calculate the fair value of stock-based payments at the date of grant. Warrant pricing models require the input of highly subjective assumptions, including the expected price volatility. For warrants granted, the Company used a variety of comparable and peer companies to determine the expected volatility. The Company believes that the use of peer company data fairly represents the expected volatility it would experience if the Company were actively publicly traded in the life sciences industry over the contractual term of the warrants. Changes in these assumptions can materially affect the fair value estimate. The Company determined that the value of the 100,000 common stock warrants granted was nominal due to the fair value of the Company’s common stock as of the grant date being nominal as a result of the priority provisions of the preferred stock.
	The remaining 1,048,698 common warrants, Class A warrants and Class B warrants to purchase common stock granted during the nine months ended September 30, 2014 were granted in conjunction with the issuance of certain convertible notes payable, consulting services and as financing fees. The warrants have an exercise price between $0.20 and $4.92 and expire between February 2021 and July 2021. The Company recorded an expense associated with the fair value of stock-based payments and uses the Black-Scholes option valuation model to calculate the fair value of stock-based payments at the date of grant. Warrant pricing models require the input of highly subjective assumptions, including the expected price volatility. For warrants granted, the Company used a variety of comparable and peer companies to determine the expected volatility. The Company believes that the use of peer company data fairly represents the expected volatility it would experience if the Company were actively publicly traded in the life sciences industry over the contractual term of the warrants. Changes in these assumptions can materially affect the fair value estimate. The Company determined that the value of the 1,048,698 common stock warrants granted was nominal due to the fair value of the Company’s common stock as of the grant date being nominal as a result of the priority provisions of the preferred stock.								The following table summarizes the common stock warrant activity during the years ended December 31, 2013 and 2012:
	Our Class A and Class B warrants to purchase common stock have a conversion price adjustment provision that falls within the scope of ASC 815. They are accounted for as liabilities and are recorded at fair value at each reporting date. The warrants had nominal value on the date of issuance and the subsequent reporting period and no liability was recorded. The liability was revalued at September 30, 2014 and the change in the fair value of the warrant liability was included as a component of Other income (expense). The change in fair value of the warrant liability has no effect on the Company’s cash flows.
	The following summarizes the change in the value of the warrant liability:
										Common		Weighted		Weighted
										Stock		Average		Average
	Balance at December 31, 2013	$	-							Warrants		Exercise		Remainder
	Issuance of warrants		-									Price		Contractual
	Change in fair value of warrant liability		13,900,400											Term in
														Years
	Balance at September 30, 2014	$	13,900,400						As of December 31, 2012:
									Warrants Outstanding as of January 1, 2012		174,420	$	10		4.8
	The Company estimates the fair value of the warrants using the Black-Scholes option valuation model utilizing the fair value of underlying common stock. Black-Scholes has inherent limitations for use in the case of a warrant with a price protection provision, since the model is designed to be used when the inputs to the model are static throughout the life of a security. Management concluded, under the Company’s facts and circumstances, that the estimated fair values of the warrants using the Black-Scholes option-pricing model approximates, in all material respects, the values determined using a Monte Carlo valuation model. The estimates in the Black-Scholes option-pricing model and the Monte Carlo valuation model are based, in part, on assumptions, including but not limited to stock price volatility, the expected life of the warrants, the risk free rate and the fair value of the equity stock underlying the warrants.								Granted		-		-		-
	The following is the weighted average of the assumptions used in calculating the fair value of the Class A and Class B warrants as of September 30, 2014 using the Black-Scholes method:								Exercised		-		-		-
									Expired		-		-		-
	Fair Market Value	$	4.94						Warrants outstanding as of December 31, 2012		174,420	$	10		3.8
	Exercise Price	$	0.20 - $4.92
	Risk Free Rate		2.2	%					As of December 31, 2013:
	Dividend Yield		0	%					Warrants Outstanding as of January 1, 2013		174,420	$	10		3.8
	Expected Volatility		50.27	%					Granted		100,000	$	2		7
	Contractual Term		6.75 years						Exercised		-		-		-
	In September 2014, certain warrants previously issued were amended to eliminate a clause that would cancel the warrant upon the completion of an initial public offering. The Company recorded an expense for the incremental fair value based on the difference between the fair value of the modified award and the fair value of the original award immediately before it was modified. The Company uses the Black-Scholes option valuation model to calculate the fair value of stock-based payments at the date of grant. Warrant pricing models require the input of highly subjective assumptions, including the expected price volatility. For warrants granted, the Company used a variety of comparable and peer companies to determine the expected volatility. The Company believes that the use of peer company data fairly represents the expected volatility it would experience if the Company were actively publicly traded in the life sciences industry over the contractual term of the warrants. Changes in these assumptions can materially affect the fair value estimate. The Company determined the incremental fair value of the warrants to be $25,061 which was expensed in the period as the warrants were fully vested.								Expired		-		-		-
	The following is the weighted average of the assumptions used in calculating the fair value of the warrants modified in September 2014 using the Black-Scholes method:
									Warrants outstanding as of December 31, 2013		274,420	$	8		4.2
	Fair Market Value	$	4.94						The following table summarizes the preferred stock warrant activity during the years ended December 31, 2013 and 2012:
	Exercise Price	$	10
	Risk Free Rate		0.61	%
	Dividend Yield		0	%						Preferred		Weighted		Weighted
	Expected Volatility		37.23	%						Stock		Average		Average
	Contractual Term		1.97 years							Warrants		Exercise		Remainder
	The following table summarizes the common stock warrant activity during the nine months ended September 30, 2014:											Price		Contractual
														Term in
														Years
		Common			Weighted		Weighted		As of December 31, 2012:
		Stock			Average		Average		Warrants Outstanding as of January 1, 2012		2,231,727	$	0.16		5.1
		Warrants			Exercise		Remainder		Granted		-		-		-
					Price		Contractual		Exercised		-		-		-
							Term in		Expired		-		-		-
							Years
	As of September 30, 2014:								Warrants outstanding as of December 31, 2012		2,231,727	$	0.16		4.1
	Warrants Outstanding as of January 1, 2014		274,420		$	7.08		4.2
	Granted		3,904,362		$	2.69		6.7	As of December 31, 2013:
	Exercised		-			-		-	Warrants Outstanding as of January 1, 2013		2,231,727	$	0.16		4.1
	Expired		-			-		-	Granted		-		-		-
									Exercised		-		-		-
	Warrants outstanding as of September 30, 2014		4,178,782		$	2.98		6.2	Expired		-		-		-
	The following table summarizes the preferred A stock warrant activity during the nine months ended September 30, 2014:								Warrants outstanding as of December 31, 2013		2,231,727	$	0.16		3.1
		Preferred			Weighted		Weighted
		Stock A			Average		Average
		Warrants			Exercise		Remainder
					Price		Contractual
							Term in
							Years
	As of September 30, 2014:
	Warrants Outstanding as of January 1, 2014		2,231,727		$	0.16		3.1
	Granted		-			-		-
	Exercised		-			-		-
	Expired		-			-		-
	Warrants outstanding as of September 30, 2014		2,231,727		$	0.16		3.1
	The following table summarizes the preferred D stock warrant activity during the nine months ended September 30, 2014:
		Preferred			Weighted		Weighted
		Stock D			Average		Average
Warrants		Exercise			Remainder
		Price			Contractual
					Term in
					Years
As of September 30, 2014:
Warrants Outstanding as of January 1, 2014		-			-		-
Granted		7,200,000		$	0.025		6.8
Exercised		-			-		-
Expired		-			-		-
Warrants outstanding as of September 30, 2014		7,200,000		$	0.025		6.8

Employee_Stock_Options

Employee Stock Options	9 Months Ended													12 Months Ended
	Sep. 30, 2014													Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Employee Stock Options	NOTE 8    EMPLOYEE STOCK OPTIONS													NOTE 10    EMPLOYEE STOCK OPTIONS
	The Company has two stock based employee compensation plans pursuant to which stock option grants may be made. Under both the 2014 and the 2006 Stock Option Plan certain employees and non-employee directors have been granted options to purchase common stock. The Company has 578,750 employee stock options outstanding as of September 30, 2014. All options vest in installments over a four year period and expire ten years from the date of grant.													The Company has a stock based employee compensation plan pursuant to which stock option grants may be made. Under the 2006 Stock Option Plan certain employees and non-employee directors have been granted options to purchase common stock. The Company has 115,750 and 110,750 employee stock options outstanding as of December 31, 2013 and 2012, respectively. All options vest in installments over a four year period and expire ten years from the date of grant.
	In September 2014, the Company completed a tender offer to eligible employees to exchange 103,250 employee stock options held by such employees under the 2006 Stock Option Plan for new options under the 2014 Stock Option Plan. The new options have an exercise price of $3.50 with all other terms the same as the original terms under the 2006 Option Plan. These transactions are accounted for under the provisions of FASB ASC 718 as a modification of a stock based compensation award and require the Company to record an expense for the incremental fair value based on the difference between the fair value of the modified award and the fair value of the original award immediately before it was modified. The Company uses the Black-Scholes option valuation model to calculate the fair value of stock-based payments at the date of grant. Option pricing models require the input of highly subjective assumptions, including the expected price volatility. For options modified, the Company used a variety of comparable and peer companies to determine the expected volatility. The Company believes that the use of peer company data fairly represents the expected volatility it would experience if the Company were actively publicly traded in the life sciences industry over the expected term of the options. The Company has no historical data regarding the expected life of the options and therefore used the simplified method of calculating the expected life. Changes in these assumptions can materially affect the fair value estimate. The Company determined the incremental fair value of the options to be $223,031 which was expensed in the period as the options are fully vested.													On October 30, 2013 an employee was awarded 5,000 common stock options under the 2006 Stock Option plan with an exercise price of $2.00 that expire in October 2023. The Company accounts for employee stock options according to FASB ASC 718 which requires the Company to calculate the fair value of the stock options on the date of grant and amortize over the vesting period of the options. The Company determined the value of the 5,000 options granted was nominal due to the fair value of the Company’s common stock as of the grant date being nominal as a result of the priority provisions of the preferred stock. The Company used a variety of comparable and peer companies to determine the expected volatility. The Company believes the use of peer company data fairly represents the expected volatility it would experience if the Company was more actively publicly traded in the life sciences industry over the expected life of the options. The Company has no historical data regarding the expected life of the options and therefore used the simplified method of calculating the expected life. The risk free rate was calculated using the U.S. Treasury constant maturity rates similar to the expected life of the options, as published by the Federal Reserve.
	The following is the weighted average of the assumptions used in calculating the fair value of the options modified in September 2014 using the Black-Scholes method:													The following table summarizes the Company’s total option activity for the years ended December 31, 2013 and 2012:
	Fair Market Value	$	4.94												Options		Weighted		Weighted
	Exercise Price	$	3.5														Average		Average
	Risk Free Rate		1.06	%													Exercise		Remaining
	Dividend Yield		0	%													Price		Contractual
	Expected Volatility		46.31	%															Term in
	Contractual Term		2.74 years																Years
														As of December 31, 2012:
	The following table summarizes the Company’s total option activity for the nine months ended September 30, 2014:													Options outstanding as of January 1, 2012		110,750	$	32		8.2
														Granted		-		-		-
														Exercised		-		-		-
		Options			Weighted				Weighted					Expired		-		-		-
					Average				Average
					Exercise				Remaining					Options outstanding as of December 31, 2012		110,750	$	32		7.2
					Price				Contractual
									Term in					As of December 31, 2013:
									Years					Options outstanding as of January 1, 2013		110,750	$	32		7.2
	As of September 30, 2014:													Granted		5,000		2		9.8
	Options outstanding as of January 1, 2014		115,750		$	30.7				6.3				Exercised		-		-		-
	Granted		586,250		$	2.2				10				Expired		-		-		-
	Exercised		-			-				-
	Cancelled		123,250		$	27.13				6.1				Options outstanding as of December 31, 2013		115,750	$	30		6.3
	Options outstanding as of September 30, 2014		578,750		$	2.65				8.7				Outstanding and exercisable stock options as of December 31, 2013 and 2012 are as follows:
	Outstanding and exercisable stock options as of September 30, 2014 are as follows:
															Options Outstanding						Options Exercisable
															Number of		Remaining		Exercise		Number of		Exercise
		Options Outstanding									Options Exercisable				Options		Life		Price		Options		Price
		Number of			Remaining		Exercise				Number of	Exercise			Outstanding		(Years)				Exercisable
		Options			Life		Price				Options	Price		31-Dec-12		110,750		7.2	$	32		78,049	$	32
		Outstanding			(Years)						Exercisable			31-Dec-13		115,750		6.3	$	30		106,570	$	32
	30-Sep-14		578,750		8.7		$	2.65			110,667	$	5.43
	The estimated fair value of the Company stock options, less expected forfeitures, is amortized over the options vesting period on the straight-line basis. The Company recognized the following equity-based compensation expenses during the nine months ended September 30, 2014 and 2013:													The estimated fair value of the Company stock options, less expected forfeitures, is amortized over the options vesting period on the straight-line basis. The Company recognized the following equity-based compensation expenses during the years ended December 31, 2013 and 2012:
		Nine Months Ended September 30,													Year Ended December 31,
		2014			2013										2013		2012
	Stock based compensation expense	$	242,696		$	83,318								Stock based compensation expense	$	111,091	$	111,091
	As of September 30, 2014 and 2013, there were $154 and $47,591 of total unrecognized compensation cost with a remaining vesting period of 0.04 and 0.43 years, respectively. As of September 30, 2014, there was $148,560 in intrinsic value of outstanding and vested stock options.													Income tax benefit recognized related to stock-based compensation		-		-
														Income tax benefit realized from the exercising and vesting of options		-		-
														As of December 31, 2013 and 2012, there were $19,818 and $130,909 of total unrecognized compensation cost with a remaining vesting period of 0.3 and 1.2 years, respectively. As of December 31, 2013, there was no intrinsic value of outstanding and vested stock options.

Notes_Payable_Related_Party

Notes Payable - Related Party	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Related Party Transactions [Abstract]
Notes Payable - Related Party	NOTE 5    NOTES PAYABLE—RELATED PARTY	NOTE 11    RELATED PARTY TRANSACTIONS
	In July 2014, the Company entered into a note agreement for $500,000 with Spring Forth Investments, LLC a company owned by Mr. David Spafford, a director. The maturity date for the note is July 18, 2015. The note pays interest at an annual rate of 20% and shall be paid monthly. The Company may extend the due date of the note to July 18, 2016 by giving notice no later than April 18, 2015 and paying an extension fee of $10,000. The Company prepaid the last three months of interest for a total of $25,000 at the time of issuance of the note. As additional consideration for the note, the Company issued 4,000,000 Series D preferred stock units (which are separable into 4,000,000 shares of Series D preferred stock, 20,000 Class A warrants to purchase a share of common stock at $4.92 and 20,000 Class B warrants to purchase a share of common stock at $0.20) at a value of $100,000 or $0.025 per unit. The Series D preferred stock units were accounted as a debt discount to be amortized over the life of the note. As of September 30, 2014 the unamortized debt discount was $83,333.	During 2013 the Company issued convertible promissory notes to entities controlled by Steven Aldous and David Spafford, two of the Company’s directors. The Company issued promissory notes to SSA Ventures, LLC and SBS Charitable Remainder Trust U/A/D November 27, 1995 (entities controlled by Mr. Aldous) reflecting obligations of $571,000 and $2,000,000, respectively. The Company also issued a promissory note to Bourne Spafford Charitable Trust U/A/D May 15, 1995 (controlled by Mr. Spafford) reflecting an obligation of $200,000. Each of these notes had an 8% interest rate and were converted into 116,565,430 shares of Series C and Series C-1 preferred stock at a conversion price of $0.0246 per share.
		During 2012 the Company issued various convertible promissory notes to Spring Forth Investments and the Bourne Spafford Charitable Trust U/A/D May 15, 1995 (entities controlled by Mr. Spafford,) in the total amount of $2,880,000. The Company also issued various convertible promissory notes to SSA Ventures, LLC (entity controlled by Mr. Aldous) in the total amount of $1,213,333. All of the notes bore interest at 8%. On December 31, 2012, the principal plus accrued interest of $92,355 was converted into 26,160,555 shares of Series B preferred stock at a conversion price of $0.16 per share.
		During 2012 the Company issued various convertible promissory notes to Spring Forth Investments (entity controlled by Mr. Spafford,) and to SSA Ventures, LLC (entity controlled by Mr. Aldous) in the total amount of $800,000 each. All of the notes bore interest at 8%. On December 31, 2012, the principal plus accrued interest of $95,848 was converted into 10,599,058 shares of Series A preferred stock and convertible promissory notes issued in 2011 in the amount of $1,250,000 for Spring Forth Investments and $1,250,000 for SSA Ventures, LLC along with interest in the amount of $271,970 were converted into 17,324,812 shares of Series A preferred stock at a conversion price of $0.16 per share.
		On December 31, 2012 the Company issued 10,416,667 shares of Series B preferred stock to SSA Ventures, LLC pursuant to a subscription receivable in the amount of $1,666,667 or $0.16 per share. The subscription receivable for these shares was subsequently paid with cash in January and February 2013.
		Ryan Ashton, the Chief Executive Officer of the Company, and David Spafford, a director of the Company, each personally guaranteed the obligations of the Company under a sale-leaseback agreement. On November 25, 2013, the Company issued Mr. Ashton warrants to purchase 50,000 shares of common stock and Mr. Spafford warrants to purchase 50,000 shares of common stock, each in compensation for their personal guarantees of the obligations of the Company under the sale-leaseback agreement. The warrants have an exercise price of $2.00 and expire seven years from the date of grant.
		The Company’s obligations pursuant to its sale-leaseback agreement described in Note 6 are secured by letters of credit (Letters of Credit) in an aggregate amount of $3,000,000. The Letters of Credit were issued by a bank at the behest of a non-profit foundation (the “Foundation”) and Spring Forth Investments. The Company is obligated to reimburse the Foundation and Spring Forth Investments for any draws made under the Letters of Credit pursuant to two reimbursement agreements between the Company and the Foundation and Spring Forth Investments dated October 30, 2013. David Spafford, one of our directors, and his wife, Susan Spafford, have been designated by the Foundation as “Founding Trustees” under its bylaws and have authority to control certain activities of the Foundation. Our obligations under the reimbursement agreements are secured by a security interest in all of our assets pursuant to a Security Agreement dated October 30, 2013. As of December 31, 2013, no draws on the line of credit had taken place.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 12    INCOME TAXES
	The Company utilizes the asset and liability approach to measuring deferred tax assets and liabilities based on temporary differences existing at each balance sheet date using currently enacted tax rates in accordance with FASB ASC 740. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.
	The income tax expense for the years ended December 31, 2013 and 2012 consists of the following:
		2013			2012
	Current
	Federal	$	-		$	-
	State and Local		1,250			100
			1,250			100
	Deferred
	Federal		-			-
	State and Local		-			-
			-			-
		$	1,250		$	100
	The following is a reconciliation of the reported amount of income tax expense (benefit) for the years ended December 31, 2013 and 2012 to the amount of income tax expenses that would result from applying the statutory rate to pretax income.
	The components of the Company’s deferred tax assets for the years ended December 31, 2013 and 2012 are as follows:
		2013			2012
	Current deferred tax assets:
	Allowance for doubtful accounts	$	2,035		$	-
	Accrued vacation		131,302			86,052
	Accrued personal property tax		37,012			18,823
	Total current deferred tax assets		170,349			104,875
	Non-current deferred tax assets
	Net operating losses		13,674,825			10,243,639
	Depreciation and amortization		15,935			53,509
	Other		171			171
	Total non-current deferred tax assets		13,690,931			10,297,319
	Total deferred tax assets		13,861,280			10,402,194
	Less: Valuation allowance		(13,861,280	)		(10,402,194	)
	Net deferred tax assets	$	-		$	-
	Reconciliation of reported amount of income tax expense for the years ended December 31, 2013 and 2012 consists of the following:
		2013			2012
	Benefit for income taxes computed at federal statutory rate	$	3,672,568		$	1,910,905
	State income taxes, net of federal tax benefit		248,065			187,604
	Non-deductible expenses		(7,473	)		(6,896	)
	Increase in valuation allowance		(3,914,410	)		(2,091,713	)
	Provision for income taxes	$	(1,250	)	$	(100	)
	Effective tax rate		(0.03	)%		(0.01	)%
	As of December 31, 2013 the Company has generated operating losses. As a result the Company has recorded a full valuation allowance against its net deferred tax assets as of December 31, 2013 and 2012.
	As of December 31, 2013 and 2012, the Company has a net operating loss carry forwards for Federal income tax purposes of $37.8 million and $28.3 million, respectively, which expire in varying amounts during the tax years 2023 through 2033. The Company has net operating loss carry forwards for State income tax purposes of $26.3 million and $18.6 million which expire in varying years from 2023 to 2033.
	Under FASB ASC 740, tax benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon ultimate settlement. Unrecognized tax benefits are tax benefits claimed in the Company’s tax returns that do not meet these recognition and measurement standards. As of December 31, 2013 and 2012, the Company has no liabilities for unrecognized tax benefits.
	The Company’s policy is to recognize potential interest and penalties accrued related to unrecognized tax benefits within income tax expense. For the years ended December 31, 2013, and 2012, the Company did not recognize any interest or penalties in its statement of operations, nor did it have any interest or penalties accrued in its balance sheet at December 31, 2013 and 2012 relating to unrecognized tax benefits.
	The tax years 2010-2013 remain open to examination for federal income tax purposes and by the other major taxing jurisdictions to which the Company is subject.

Legal_Proceedings

Legal Proceedings	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	NOTE 10    LEGAL PROCEEDINGS	NOTE 13    LEGAL PROCEEDINGS
	We are not currently a party to any pending or threatened legal proceeding or regulatory or government investigations. We may become involved in litigation from time to time relating to claims arising in the ordinary course of our business. We do not believe that the ultimate resolution of such claims would have a material effect on our business, results of operations, financial condition or cash flows. However, the results of these matters cannot be predicted with certainty, and an unfavorable resolution of one or more of these matters could have a material effect on our business, results of operations, financial condition and cash flows.	We are not currently a party to any pending or threatened legal proceeding or regulatory or government investigations. We may become involved in litigation from time to time relating to claims arising in the ordinary course of our business. We do not believe that the ultimate resolution of such claims would have a material effect on our business, results of operations, financial condition or cash flows. However, the results of these matters cannot be predicted with certainty, and an unfavorable resolution of one or more of these matters could have a material effect on our business, results of operations, financial condition and cash flows.

Geographic_Information

Geographic Information	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]
Geographic Information	NOTE 14    GEOGRAPHIC INFORMATION
	The Company has both domestic (U.S.) and international customers for its products. Sales for the years ended December 31, 2013 and 2012 were as follows:
		2013		2012
	Domestic sales	$	736,215	$	27,319
	International sales		24,431		11,348
	Total sales	$	760,646	$	38,667

Subsequent_Events

Subsequent Events	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Subsequent Events [Abstract]
Subsequent Events	NOTE 12    SUBSEQUENT EVENTS	NOTE 15    SUBSEQUENT EVENTS
	On October 8, 2014, the Company completed its initial public offering, whereby the Company sold 1,150,000 shares of its common stock and 1,150,000 Series A Warrants, which were sold in combinations of one share of common stock and one Series A Warrant at a public offering price of $7.00 per share. Each Series A Warrant is exercisable for one share of common stock and one Series B Warrant. In addition, the underwriter exercised its option to purchase 172,500 Series A Warrants. The shares began trading on the NASDAQ Capital Market on October 9, 2014. The aggregate net proceeds received by the Company from the offering were approximately $6.4 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. Upon the closing of the initial public offering, all outstanding shares of convertible preferred stock converted into 3,616,702 shares of common stock and warrants exercisable for preferred stock converted into 47,158 warrants for common stock.	With respect to the audited financial statements as of and for the year ended December 31, 2013 the Company evaluated subsequent events through June 6, 2014.
	In October 2014, the Company, in connection with the initial public offering, issued to the underwriters warrants exercisable for up to 57,500 shares of the Company’s common stock with an exercise price of $8.75. The warrants are not exercisable prior to October 2015 and will expire in October 2019.	The Company issued 14,888,211 shares of Series C Preferred Stock from January 24, 2014 through February 18, 2014, when the Company closed its Series C Preferred round for $366,250 or $0.0246 per share.
	In October 2014, Class B Warrants were exercised for 150,000 shares of common stock for proceeds in the amount of $30,000 or $0.20 per share.	In February and March 2014, the Company issued Convertible Notes in the amount of $400,000. The maturity date for the notes is March 10, 2015, or upon a qualified equity financing of at least $5 million. The notes pay interest at an annual rate 8%. In addition the Note Holders received warrants to purchase 50,000 of common stock at $2.00 per share which expire seven years from the date of issuance. The notes are convertible, at the option of the holder, into shares of Series C preferred stock at a conversion price of $0.0246 per share which is convertible into common stock at a ratio of 200:1, or if there is a qualified equity financing, into shares of the equity securities at the price per share at which the equity securities are issued in the qualified equity financing.
	In October 2014, the Company issued 17,500 non-qualified stock options under the Company’s Omnibus Plan to each Non-Employee Director. A total of 52,500 options were issued with an exercise price of $7.00 per share that vest quarterly over three years and expire in October 2024.	In March 2014, the Company issued short terms notes payable to David Spafford, a director, in the amount of $350,000 and to Ryan Ashton, our Chief Executive Officer, in the amount of $40,000. The notes were unsecured, accrue no interest and were to be repaid on or before May 1, 2014. In April 2014, the Company retired the $390,000 of short term related party notes payable by paying $350,000 cash to David Spafford and $40,000 to Ryan Ashton.
	In October 2014, the Company named Jeffrey A. Rona as Chief Financial Officer of the Company. As part of his hiring, Mr. Rona was granted 50,784 stock options under the Company’s Omnibus Plan with an exercise price of $7.00 per share that vest 25% immediately and the remaining 75% over a three year period and expire in October 2024.	In April 2014, the Company filed a fourth amended and restated Certificate of Incorporation authorizing a modification to the number of authorized shares of each class of stock and each series of preferred stock. In addition, a fifth series of preferred stock was authorized and designated as Series D preferred stock. The preferred stock dividends were changed such that the dividends are non-cumulative and shall be the per annum rate of 8% per share of the original series issue price.
	In October 2014, the Company filed a seventh amended and restated Certificate of Incorporation which among other things made a modification to the number of authorized shares of common stock and preferred stock. The number of common shares authorized was amended to 50,000,000 shares and the number of preferred shares authorized was amended to 5,000,000 shares. The amendment also eliminates all classes of preferred stock.
		The Company initiated a Series D Preferred Stock offering in April 2014. The Company has sold 89,400,000 Series D units (which are separable into 89,400,000 Series D Preferred Shares that convert into common stock at a ratio of 200:1, 447,000 post-split Class A warrants to purchase a share of common stock at $4.92 per share and 447,000 post-split Class B warrants to purchase a share of common stock at $0.20 per share) for gross proceeds of $2,235,000 and after deducting offering costs and expenses, the Company has received $2,044,477 of net proceeds.
		In April 2014, the Company issued warrants to certain individuals for consulting services to purchase 9,278 shares common stock at $2.00 per share that expire seven years after the date of issuance.
		In April 2014, the Company issued stock options to certain employees to purchase 393,000 shares of common stock at $2.00 per share. These options vest over a four-year period and expire 10 years after the date of issuance.
		In April 2014, the Company entered into two Financial Advisory Agency Agreements with Rona Capital, LLC. The first agreement is for financial advisory services related to the Company’s ongoing financing activities prior to the filing of an S-1 registration with the SEC. The Company agreed to pay Rona Capital $15,000 per month plus reasonable out-or-pocket expenses. In addition, the Company issued warrants to Rona Capital to purchase between 1,800,000 Series D units (which are separable into 1,800,000 Series D Preferred Shares that convert into common stock at a ratio of 200:1, 9,000 post-split Class A warrants and 9,000 post-split Class B warrants) and 7,200,000 Series D units (which are separable into 7,200,000 Series D Preferred Shares, 36,000 post-split Class A warrants and 36,000 post-split Class B warrants), upon the completion of an S-1 filing with the SEC. The Company will also indemnify Rona Capital for claims arising from the agreement, subject to certain exceptions. This agreement will terminate upon the final closing of the Series D Preferred Stock financing.
		The Company has also entered into a second Financial Advisory Agency Agreement with Rona Capital effective in June 2014, wherein Rona Capital will provide the Company with financial advisory services related to the Company’s ongoing financing activities. The Company will pay Rona Capital $15,000 per month and additional cash amounts on the achievement of specified milestones, including $50,000 upon the filing of an S-1 with the SEC and $100,000 upon the closing of an initial public offering. The Company has also agreed to issue warrants to Rona Capital to purchase shares of the Company’s common stock such that Rona Capital shall own 1% of the Company’s outstanding equity that vest upon continued service to the Company as a consultant.
		In April 2014, the Company completed a second sale-leaseback transaction. The Company sold 75 analyzers for gross proceeds of $1,500,000. Concurrent with the transaction, the Company repaid two equipment leases for a total of $125,751. The terms of the sale-leaseback agreement requires the Company to pay monthly lease payments of $64,665 for two years.

Fair_Value

Fair Value	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]
Fair Value	NOTE 9    FAIR VALUE
	FASB ASC 820 defines fair value, establishes a framework for measuring fair value under U.S. generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined under FASB ASC 820 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under FASB ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, with the first two inputs considered observable and the last input considered unobservable, that may be used to measure fair value as follows:
		•	Level one—Quoted market prices in active markets for identical assets or liabilities;
		•	Level two—Inputs other than level one inputs that are either directly or indirectly observable; and
		•	Level three—Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.
	Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter. The Company issued Class A and Class B warrants to purchase common stock as well as warrants to purchase Series D preferred stock. These warrants have a conversion price adjustment provision that in the event the Company sells shares of any additional stock, subject to certain exceptions, at a price per share less than the original issue price of the respective warrant, the conversion price shall be adjusted to a price equal to the price paid per share for such additional stock. The Company has determined that these warrants fall within the scope of ASC 815. The Company will account for them as liabilities and record them at fair value measured at the transaction date and again at each reporting period. The fair value of the warrants were determined using estimates and assumptions that are not readily available in public markets and the Company has designated this liability as Level 3. The assumptions used for the fair value calculation as well as the changes in the value of the warrant liability are shown in NOTE 7 WARRANTS.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation	Basis of Presentation
	These condensed unaudited financial statements have been prepared to reflect the financial position, results of operations and cash flows of the Company as of September 30, 2014 and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information. The accompanying condensed financial statements and notes are unaudited. In management’s opinion, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of September 30, 2014 and its results of operations and cash flows for the nine months ended September 30, 2014 and 2013. The results for the nine months ended September 30, 2014 are not necessarily indicative of the results expected for the full fiscal year or any other interim period.	These financial statements have been prepared to reflect the financial position, results of operations and cash flows of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
Use of Estimates		Use of Estimates
		The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Such estimates include the sales return reserve, accounts receivable and inventory reserves, intangible assets and other long lived assets, legal and regulatory contingencies, income taxes and others. These estimates and assumptions are based on management’s best estimates and judgments. Actual amounts and results could differ from those estimates.
Cash and Cash Equivalents		Cash and Cash Equivalents
		The Company considers highly liquid investments with insignificant interest rate risk and original maturities to the Company of three months or less to be cash equivalents. Cash equivalents consist primarily of interest and non-interest bearing bank accounts held in checking, savings and money market accounts. These assets are generally available on a daily or weekly basis and are highly liquid in nature. If the balances are greater than $250,000, the Company does not have FDIC coverage on the entire amount of bank deposits.
Accounts Receivable		Accounts Receivable
		Accounts receivable are generated from the sale of single use diagnostic test cartridges to end users in the United States and to a network of distributors outside the United States. These accounts receivable are recorded at the invoiced amount, net of allowances for doubtful amounts. The Company routinely reviews outstanding accounts
		receivable balances for estimated uncollectible accounts and establishes or adjusts the allowances for doubtful accounts receivable using the specific identification method and records a reserve for amounts not expected to be fully recovered. Actual balances are not applied against the reserve until substantially all collection efforts have been exhausted. The Company does not have customer acceptance provisions, but it does provide its customers a limited right of return for defective diagnostic test cartridges.
		The Company accrues an estimated amount for sales returns and allowances related to defective product at the time of sale based on its ability to estimate sales returns and allowances using current and historical information. The reserve for sales returns and allowances is included as a reduction to revenue and accounts receivable, net.
		The balance of accounts receivable at December 31, 2013 and 2012, net of an allowance for doubtful accounts of $5,482 and $0, was $184,415 and $102,976, respectively.
Inventories		Inventories
		Inventories are stated at the lower of cost or market with cost determined according to the average cost method. Manufactured inventory consists of raw material, direct labor and manufacturing overhead cost components. The Company reviews the components of its inventory on a regular basis for excess and obsolete inventory and makes appropriate adjustments when necessary. Inventories consisted of the following at December 31, 2013 and 2012:
			December 31,
			2013		2012
		Raw materials	$	278,947	$	80,909
		Work-in-process		39,192		13,171
		Finished goods		2,100		-
		Total inventories	$	320,239	$	94,080
Property and Equipment		Property and Equipment
		Property and equipment is recorded at cost and depreciated over the estimated useful lives of the assets (which range from three to ten years) using the straight-line method. Amortization of leasehold improvements is computed on the straight-line method over the shorter of the lease term or estimated useful lives of the assets. The analyzers that the Company manufactures and retains title over are placed with customers and are recorded in property and equipment under “Analyzers.” The materials used for the manufacture of the analyzers are recorded in property and equipment under “Construction in progress.” Major renewals and betterments are capitalized and depreciated over their estimated useful lives while minor expenditures for maintenance and minor repairs are charged to operations as incurred.
		The Company classifies assets to be sold as assets held for sale when (i) Company management has approved and commits to a plan to sell the asset, (ii) the asset is available for immediate sale in its present condition and is ready for sale, (iii) an active program to locate a buyer and other actions required to sell the asset have been initiated, (iv) the sale of the asset is probable, (v) the asset is being actively marketed for sale at a price that is reasonable in relation to its current fair value, and (vi) it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn. Assets classified as held for sale are recorded at the lower of the carrying amount or fair value less the cost to sell and are a component of prepaid and other current assets in the balance sheets. The Company did not have any assets classified as held for sale as of December 31, 2013 and 2012.
Intangible Assets		Intangible Assets
		The Company records its intangible assets at cost which consist of two licensing and royalty agreements for certain intellectual property rights used in the development and manufacture of our products. These intangible assets are being amortized over a period of seven years from the date that the technology licenses became effective. As of December 31, 2013 and 2012, intangible assets totaled $600,000 and $375,000 valued at cost, less accumulated amortization of $265,975 and $168,296, respectively. The Company estimates that approximately $118,409 will be amortized per year. The Company recorded amortization associated with these agreements of $97,680 and $60,563 for the years ended December 31, 2013 and 2012, respectively.
Impairment of Long Lived Assets		Impairment of Long Lived Assets
		Long-lived tangible assets, including property and equipment, and definite-lived intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. The Company regularly evaluates whether events or circumstances have occurred that indicate possible impairment and relies on a number of factors, including expected future operating results, business plans, economic projections, and anticipated future cash flows. The Company uses an estimate of the future undiscounted net cash flows and comparisons to like-kind assets, as appropriate, of the related asset over the remaining life in measuring whether the assets are recoverable. Measurement of the amount of impairment, if any, is based upon the difference between the asset’s carrying value and estimated fair value. Fair value is determined through various valuation techniques, including cost-based, market and income approaches as considered necessary.
Fair Value of Financial Instruments		Fair Value of Financial Instruments
		The Company measures at fair value certain of its financial and non-financial assets and liabilities by using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price, based on the highest and best use of the asset or liability. The levels of the fair value hierarchy are:
		Level 1—Quoted market prices in active markets for identical assets or liabilities;
		Level 2—Significant other observable inputs (e.g. quoted prices for similar items in active markets, quoted prices for identical or similar items in markets that are not active, inputs other than quoted prices that are observable, such as interest rate and yield curves, and market-corroborated inputs); and
		Level 3—Unobservable inputs in which there is little or no market data, which require the reporting unit to develop its own assumptions.
Revenue Recognition		Revenue Recognition
		The Company derives its product revenue from the sale of single use diagnostic test cartridges sold through our dedicated sales force, except in the European Union where the Company sells through a network of distributors. Product revenue is recognized when all four of the following criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery of the products has occurred; (3) the selling price of the product is fixed or determinable; and (4) collectability of that price is reasonably assured. Change in title to the product and recognition of revenue from sales of diagnostic test cartridges occurs at the time of shipment. Shipping and handling fees and related freight costs and supplies for test kits are billed to customers. Additional costs associated with shipping products to customers as well as the 2.3% excise tax on the sale of medical devices in the United States are included as a component of cost of goods sold.
Research and Development Costs		Research and Development Costs
		Research and development costs are charged to operations as incurred. Research and development costs include, among other things, salaries and wages for research scientists and staff (including stock-based compensation), materials and supplies used in the development of new products, developing and validating the manufacturing process, costs for clinical trials, and costs for research and development facilities and equipment.
Stock Based Compensation		Stock Based Compensation
		The Company has accounted for stock-based compensation under the provisions of Financial Accounting Standards Board Accounting Standards Codification (“FASB ASC”) 718, “Compensation – Stock Compensation”. This standard requires the Company to record an expense associated with the fair value of stock- based compensation over the requisite service period. The Company uses the Black-Scholes option valuation model to calculate the value of options at the date of grant. Option pricing models require the input of highly subjective assumptions, including the estimated fair value of the Company’s common stock on the date of grant, the expected term of the stock option, and the expected price volatility of the Company’s common stock over the period equal to the expected term of the grant. Changes in these assumptions can materially affect the fair value estimate. The Company estimates forfeitures at the date of grant and revises the estimates, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
Financial Instruments and Concentration of Credit Risk		Financial Instruments and Concentration of Credit Risk
		The Company’s financial instruments include cash and cash equivalents, accounts receivable, and accounts payable. The carrying amount of cash and cash equivalents, accounts receivable, and accounts payable approximate fair value because of their immediate or short-term maturities.
		All of the Company’s accounts receivable result from sales in the normal course of business to its customers primarily throughout the United States. The Company attempts to limit its credit risk by performing credit evaluations of new customers and maintaining adequate allowances for potential credit losses. As of December 31, 2013, 25% of the accounts receivable balance resulted from one customer. As of December 31, 2012, 78% of the accounts receivable balances resulted from three customers. Historically, the Company has not experienced significant credit losses on such receivables. Allowances for bad debt in the amount of $5,482 were recorded against accounts receivable for the year ended December 31, 2013. There was no bad debt for the year ended December 31, 2012. The Company cannot ensure that such losses will not be realized in the future.
		The Company’s customers are primarily hospitals and health clinics. For the year ended December 31, 2013, 23% of revenues resulted from two customers who each accounted for more than 10% of revenues. For the year ended December 31, 2012, 58% of revenues resulted from three customers who each accounted for more than 10% of revenues.
Income Taxes		Income Taxes
		The Company accounts for income taxes under FASB ASC 740, “Income Taxes”. Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are
		expected to reverse. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is “more likely than not” that some component or all of the benefits of deferred tax assets will not be realized.
		The tax effects from an uncertain tax position can be recognized in the financial statements only if the position is more likely than not of being sustained if the position were to be challenged by a taxing authority. The Company has examined the tax positions taken in its tax returns and determined that there are no uncertain tax positions. As a result, the Company has recorded no uncertain tax liabilities in its balance sheet.
Loss per Common Share	Loss per Common Share	Loss per Common Share
	Basic loss per share (“EPS”) is computed by dividing net loss (the numerator) by the weighted average number of common shares outstanding for the period (the denominator). Diluted EPS is computed by dividing net loss by the weighted average number of common shares and potential common shares outstanding (if dilutive) during each period. Potential common shares include convertible preferred stock, stock options and warrants. The number of potential common shares outstanding is computed using the treasury stock method.	Basic loss per share (“EPS”) is computed by dividing net loss, less cumulative preferred stock dividends for the period, including undeclared or unpaid cumulative dividends (the numerator) by the weighted average number of common shares outstanding for the period (the denominator). Diluted EPS is computed by dividing net loss by the weighted average number of common shares and potential common shares outstanding (if dilutive) during each period. Potential common shares include convertible preferred stock, stock options and warrants. The number of potential common shares outstanding is computed using the treasury stock method.
	As the Company has incurred losses for the nine months ended September 30, 2014 and 2013, the potentially dilutive shares are anti-dilutive and are thus not added into the loss per share calculations. As of September 30, 2014 and 2013, there were 8,141,418 and 2,082,111 potentially dilutive shares, respectively.	As the Company has incurred losses for the years ended December 31, 2013 and 2012, the potentially dilutive shares are anti-dilutive and are thus not added into the loss per share calculations. As of December 31, 2013 and 2012, there were 2,459,343 and 1,179,265 potentially dilutive shares, respectively.
New Accounting Pronouncements	New Accounting Pronouncements	New Accounting Pronouncements
	From time to time, new accounting pronouncements are issued by the FASB that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption.	From time to time, new accounting pronouncements are issued by the FASB that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption.
	In May 2014, the Financial Accounting Standards Board issued accounting guidance on revenue recognition. The amended guidance will enhance the comparability of revenue recognition practices and will be applied to all contracts with customers. Improved disclosures related to the nature, amount, timing, and uncertainty of revenue that is recognized are requirements under the amended guidance. This guidance will be effective for fiscal 2017 and will be required to be applied retrospectively. We are currently assessing the impact that this guidance will have on our financial statements at this time.	In May 2014, the Financial Accounting Standards Board issued accounting guidance on revenue recognition. The amended guidance will enhance the comparability of revenue recognition practices and will be applied to all contracts with customers. Improved disclosures related to the nature, amount, timing, and uncertainty of revenue that is recognized are requirements under the amended guidance. This guidance will be effective for fiscal 2017 and will be required to be applied retrospectively. We are currently assessing the impact that this guidance will have on our financial statements at this time.
Reverse Stock Split	Reverse Stock Split	Reverse Stock Split
	On September 5, 2014, the Company effected a reverse stock split of the Company’s common stock whereby each two hundred shares of common stock was replaced with one share of common stock (with no fractional shares issued). The par value and authorized shares of the common stock were not adjusted as a result of the reverse stock split. All common share, options, warrants and per share amounts for all periods presented in these financial statements have been adjusted retroactively to reflect the reverse stock split. The convertible preferred stock was not included in the reverse stock split and the outstanding amounts have not been adjusted. However, the conversion ratio was adjusted as a result of the reverse stock split such that upon conversion, each two hundred shares of preferred stock will be converted into one share of common stock.	On September 5, 2014, the Company effected a reverse stock split of the Company’s common stock whereby each two hundred shares of stock was replaced with one share of stock (with no fractional shares issued). The par value and the authorized shares of the common and convertible preferred stock were not adjusted as a result of the reverse stock split. All common share and per share amounts for all periods presented in these financial statements have been adjusted retroactively to reflect the reverse stock split.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]
Schedule of Inventories	Inventories consisted of the following at December 31, 2013 and 2012:
		December 31,
		2013		2012
	Raw materials	$	278,947	$	80,909
	Work-in-process		39,192		13,171
	Finished goods		2,100		-
	Total inventories	$	320,239	$	94,080

Property_And_Equipment_Tables

Property And Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consisted of the following at December 31, 2013 and December 31, 2012:
		December 31,
		2013			2012
	Construction in progress	$	308,411		$	212,189
	Analyzers		1,421,293			918,940
	Computers and office equipment		244,454			219,190
	Machinery and equipment		910,643			400,154
	Leasehold improvements		366,945			326,640
	Furniture and fixtures		11,730			6,414
	Equipment under capital lease		1,462,122			188,918
			4,725,598			2,272,445
	Less: accumulated depreciation and amortization		(1,022,016	)		(541,006	)
	Total Property and equipment, net	$	3,703,582		$	1,731,439

Accrued_Expenses_Tables

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consisted of the following as of December 31, 2013 and 2012:
		December 31,
		2013		2012
	Accrued payroll	$	564,740	$	441,646
	Royalties		105,319		-
	Accrued interest		39,808		-
	Accrued property tax		99,707		50,508
	Other		6,240		100
	Total accrued liabilities	$	815,814	$	492,254

Commitments_Tables

Commitments (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]
Schedule of annual future maturities of capital leases	Annual future maturities of capital leases for the next five years are as follows:
	Years ended December 31,
	2014	$	506,506
	2015		613,433
	2016		723,938
	2017		704,988
	Total capital lease commitments		2,548,865
	Less: current portion of capital leases		(506,506	)
	Long term portion of capital leases	$	2,042,359
Schedule of operating lease commitments	Operating lease commitments for the next five years are as follows:
	Years ended December 31,
	2014	$	287,657
	2015		97,522
	2016		2,397
	2017		715
	Total operating lease commitments	$	388,291

Long_Term_Debt_Tables

Long Term Debt (Tables)	9 Months Ended							12 Months Ended
	Sep. 30, 2014							Dec. 31, 2013
Debt Disclosure [Abstract]
Summary of Purchased Certain Machinery and Equipment under Two Note Payable Agreements	The Company purchased certain machinery and equipment under two note payable agreements which consist of the following as of September 30, 2014 and December 31, 2013:							The Company purchased certain machinery and equipment under two note payable agreements which consist of the following as of December 31, 2013 and 2012:
		September 30,			December 31,				December 31,
		2014			2013				2013			2012
	Note payable, 15.2% interest, monthly payments of $ 1,328, due February 6, 2016, secured by equipment.	$	20,194		$	29,259		Note payable, 15.2% interest, monthly payments of $1,328, due February 6, 2016, secured by equipment.	$	29,259		$	-
	Note payable, 10.0% interest, monthly payments of $ 3,161, due January 1, 2016, secured by equipment.		47,124			71,072		Note payable, 10.0% interest, monthly payments of $3,161, due January 1, 2016, secured by equipment.		71,072			-
	Total notes payable		67,318			100,331		Total notes payable		100,331			-
	Less: current portion of notes payable		(48,586	)		(44,601	)	Less: current portion of notes payable		(44,601	)		-
	Long term portion of notes payable	$	18,732		$	55,730		Long term portion of notes payable	$	55,730		$	-

Warrants_Tables

Warrants (Tables)	9 Months Ended								12 Months Ended
	Sep. 30, 2014								Dec. 31, 2013
Summary of Stock Option Activity	The following table summarizes the Company’s total option activity for the nine months ended September 30, 2014:								The following table summarizes the Company’s total option activity for the years ended December 31, 2013 and 2012:
		Options			Weighted		Weighted			Options		Weighted		Weighted
					Average		Average					Average		Average
					Exercise		Remaining					Exercise		Remaining
					Price		Contractual					Price		Contractual
							Term in							Term in
							Years							Years
	As of September 30, 2014:								As of December 31, 2012:
	Options outstanding as of January 1, 2014		115,750		$	30.7		6.3	Options outstanding as of January 1, 2012		110,750	$	32		8.2
	Granted		586,250		$	2.2		10	Granted		-		-		-
	Exercised		-			-		-	Exercised		-		-		-
	Cancelled		123,250		$	27.13		6.1	Expired		-		-		-
	Options outstanding as of September 30, 2014		578,750		$	2.65		8.7	Options outstanding as of December 31, 2012		110,750	$	32		7.2
									As of December 31, 2013:
									Options outstanding as of January 1, 2013		110,750	$	32		7.2
									Granted		5,000		2		9.8
									Exercised		-		-		-
									Expired		-		-		-
									Options outstanding as of December 31, 2013		115,750	$	30		6.3
Summary of Change in the Value of the Warrant Liability	The following summarizes the change in the value of the warrant liability:
	Balance at December 31, 2013	$	-
	Issuance of warrants		-
	Change in fair value of warrant liability		13,900,400
	Balance at September 30, 2014	$	13,900,400
Common Stock Warrants
Summary of Stock Option Activity	The following table summarizes the common stock warrant activity during the nine months ended September 30, 2014:								The following table summarizes the common stock warrant activity during the years ended December 31, 2013 and 2012:
		Common			Weighted		Weighted			Common		Weighted		Weighted
		Stock			Average		Average			Stock		Average		Average
		Warrants			Exercise		Remainder			Warrants		Exercise		Remainder
					Price		Contractual					Price		Contractual
							Term in							Term in
							Years							Years
	As of September 30, 2014:								As of December 31, 2012:
	Warrants Outstanding as of January 1, 2014		274,420		$	7.08		4.2	Warrants Outstanding as of January 1, 2012		174,420	$	10		4.8
	Granted		3,904,362		$	2.69		6.7	Granted		-		-		-
	Exercised		-			-		-	Exercised		-		-		-
	Expired		-			-		-	Expired		-		-		-
	Warrants outstanding as of September 30, 2014		4,178,782		$	2.98		6.2	Warrants outstanding as of December 31, 2012		174,420	$	10		3.8
									As of December 31, 2013:
									Warrants Outstanding as of January 1, 2013		174,420	$	10		3.8
									Granted		100,000	$	2		7
									Exercised		-		-		-
									Expired		-		-		-
									Warrants outstanding as of December 31, 2013		274,420	$	8		4.2
Preferred A Stock Warrants
Summary of Stock Option Activity	The following table summarizes the preferred A stock warrant activity during the nine months ended September 30, 2014:								The following table summarizes the preferred stock warrant activity during the years ended December 31, 2013 and 2012:
		Preferred			Weighted		Weighted			Preferred		Weighted		Weighted
		Stock A			Average		Average			Stock		Average		Average
		Warrants			Exercise		Remainder			Warrants		Exercise		Remainder
					Price		Contractual					Price		Contractual
							Term in							Term in
							Years							Years
	As of September 30, 2014:								As of December 31, 2012:
	Warrants Outstanding as of January 1, 2014		2,231,727		$	0.16		3.1	Warrants Outstanding as of January 1, 2012		2,231,727	$	0.16		5.1
	Granted		-			-		-	Granted		-		-		-
	Exercised		-			-		-	Exercised		-		-		-
	Expired		-			-		-	Expired		-		-		-
	Warrants outstanding as of September 30, 2014		2,231,727		$	0.16		3.1	Warrants outstanding as of December 31, 2012		2,231,727	$	0.16		4.1
									As of December 31, 2013:
									Warrants Outstanding as of January 1, 2013		2,231,727	$	0.16		4.1
									Granted		-		-		-
									Exercised		-		-		-
									Expired		-		-		-
									Warrants outstanding as of December 31, 2013		2,231,727	$	0.16		3.1
Common Class A And B
Assumptions used in Calculating Fair Value of Warrants Granted	The following is the weighted average of the assumptions used in calculating the fair value of the Class A and Class B warrants as of September 30, 2014 using the Black-Scholes method:
	Fair Market Value	$	4.94
	Exercise Price	$	0.20 - $4.92
	Risk Free Rate		2.2	%
	Dividend Yield		0	%
	Expected Volatility		50.27	%
	Contractual Term		6.75 years
Preferred D Stock Warrants
Summary of Stock Option Activity	The following table summarizes the preferred D stock warrant activity during the nine months ended September 30, 2014:
		Preferred			Weighted		Weighted
		Stock D			Average		Average
		Warrants			Exercise		Remainder
					Price		Contractual
							Term in
							Years
	As of September 30, 2014:
	Warrants Outstanding as of January 1, 2014		-			-		-
	Granted		7,200,000		$	0.025		6.8
	Exercised		-			-		-
	Expired		-			-		-
	Warrants outstanding as of September 30, 2014		7,200,000		$	0.025		6.8
Warrant
Assumptions used in Calculating Fair Value of Warrants Granted	The following is the weighted average of the assumptions used in calculating the fair value of the warrants modified in September 2014 using the Black-Scholes method:
	Fair Market Value	$	4.94
	Exercise Price	$	10
	Risk Free Rate		0.61	%
	Dividend Yield		0	%
	Expected Volatility		37.23	%
	Contractual Term		1.97 years

Employee_Stock_Options_Tables

Employee Stock Options (Tables)	9 Months Ended											12 Months Ended
	Sep. 30, 2014											Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Stock Options Outstanding and Exercisable	Outstanding and exercisable stock options as of September 30, 2014 are as follows:											Outstanding and exercisable stock options as of December 31, 2013 and 2012 are as follows:
		Options Outstanding							Options Exercisable				Options Outstanding						Options Exercisable
		Number of			Remaining		Exercise		Number of	Exercise			Number of		Remaining		Exercise		Number of		Exercise
		Options			Life		Price		Options	Price			Options		Life		Price		Options		Price
		Outstanding			(Years)				Exercisable				Outstanding		(Years)				Exercisable
	30-Sep-14		578,750		8.7		$	2.65	110,667	$	5.43	31-Dec-12		110,750		7.2	$	32		78,049	$	32
												31-Dec-13		115,750		6.3	$	30		106,570	$	32
Schedule of Equity-Based Compensation Expenses	The estimated fair value of the Company stock options, less expected forfeitures, is amortized over the options vesting period on the straight-line basis. The Company recognized the following equity-based compensation expenses during the nine months ended September 30, 2014 and 2013:											The estimated fair value of the Company stock options, less expected forfeitures, is amortized over the options vesting period on the straight-line basis. The Company recognized the following equity-based compensation expenses during the years ended December 31, 2013 and 2012:
		Nine Months Ended September 30,											Year Ended December 31,
		2014			2013								2013		2012
	Stock based compensation expense	$	242,696		$	83,318						Stock based compensation expense	$	111,091	$	111,091
												Income tax benefit recognized related to stock-based compensation		-		-
												Income tax benefit realized from the exercising and vesting of options		-		-
Schedule of Assumptions Used in Calculation of Fair Value of the Options Exchanged	The following is the weighted average of the assumptions used in calculating the fair value of the options modified in September 2014 using the Black-Scholes method:
	Fair Market Value	$	4.94
	Exercise Price	$	3.5
	Risk Free Rate		1.06	%
	Dividend Yield		0	%
	Expected Volatility		46.31	%
	Contractual Term		2.74 years

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Income Tax Expense	The income tax expense for the years ended December 31, 2013 and 2012 consists of the following:
		2013			2012
	Current
	Federal	$	-		$	-
	State and Local		1,250			100
			1,250			100
	Deferred
	Federal		-			-
	State and Local		-			-
			-			-
		$	1,250		$	100
Components of Deferred Tax Assets	The components of the Company’s deferred tax assets for the years ended December 31, 2013 and 2012 are as follows:
		2013			2012
	Current deferred tax assets:
	Allowance for doubtful accounts	$	2,035		$	-
	Accrued vacation		131,302			86,052
	Accrued personal property tax		37,012			18,823
	Total current deferred tax assets		170,349			104,875
	Non-current deferred tax assets
	Net operating losses		13,674,825			10,243,639
	Depreciation and amortization		15,935			53,509
	Other		171			171
	Total non-current deferred tax assets		13,690,931			10,297,319
	Total deferred tax assets		13,861,280			10,402,194
	Less: Valuation allowance		(13,861,280	)		(10,402,194	)
	Net deferred tax assets	$	-		$	-
Reconciliation of Reported Amount of Income Tax Expense	Reconciliation of reported amount of income tax expense for the years ended December 31, 2013 and 2012 consists of the following:
		2013			2012
	Benefit for income taxes computed at federal statutory rate	$	3,672,568		$	1,910,905
	State income taxes, net of federal tax benefit		248,065			187,604
	Non-deductible expenses		(7,473	)		(6,896	)
	Increase in valuation allowance		(3,914,410	)		(2,091,713	)
	Provision for income taxes	$	(1,250	)	$	(100	)
	Effective tax rate		(0.03	)%		(0.01	)%

Geographic_Information_Tables

Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]
Schedule of Domestic and International Customers Products Sales	Sales for the years ended December 31, 2013 and 2012 were as follows:
		2013		2012
	Domestic sales	$	736,215	$	27,319
	International sales		24,431		11,348
	Total sales	$	760,646	$	38,667

Description_of_Business_Additi

Description of Business - Additional Information (Detail)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Description of Business [Line Items]
Date of incorporation	27-Jun-03	27-Jun-03
Nevada Corporation
Description of Business [Line Items]
Date of merger	29-Aug-08	29-Aug-08

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	9 Months Ended		12 Months Ended		0 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Sep. 05, 2014
			Agreement
Accounting Policies [Line Items]
Cash, FDIC Insured Amount			$250,000
Accounts receivable	233,426		184,415	102,976
Allowance for doubtful accounts	5,482		5,482	0
Number of licensing and royalty agreements			2
Intangible assets amortization period			7 years
Total intangible assets			600,000	375,000
Accumulated amortization			265,975	168,296
Amortization per year			118,409
Amortization of intangible assets			$97,680	$60,563
Excise tax rate			2.30%
Dilutive shares excluded from computation of earnings per share	8,141,418	2,082,111	2,459,343	1,179,265
Accounts Receivable | Customer Concentration Risk
Accounting Policies [Line Items]
Concentration risk percentage			25.00%	78.00%
Number of customers			1	3
Sales Revenue | Customer Concentration Risk
Accounting Policies [Line Items]
Concentration risk percentage			23.00%	58.00%
Number of customers			2	3
Common Stock | Subsequent Event
Accounting Policies [Line Items]
Reverse stock split ratio					0.005
Common Stock
Accounting Policies [Line Items]
Reverse stock split ratio					0.005
Preferred Stock
Accounting Policies [Line Items]
Reverse stock split ratio					0.005
Minimum
Accounting Policies [Line Items]
Estimated useful lives of assets			3 years
Maximum
Accounting Policies [Line Items]
Estimated useful lives of assets			10 years

Schedule_of_Inventories_Detail

Schedule of Inventories (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Inventory Disclosure [Abstract]
Raw materials		$278,947	$80,909
Work-in-process		39,192	13,171
Finished goods		2,100
Total inventories	$381,952	$320,239	$94,080

Going_Concern_Additional_Infor

Going Concern - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Liquidity Disclosure Going Concern [Abstract]
Net loss	($17,248,524)	($2,428,417)	($23,230,902)	($6,750,136)	($9,561,280)	($7,270,030)
Accumulated deficit	($65,507,780)		($65,507,780)		($42,276,878)	($32,715,598)

Schedule_of_Property_and_Equip

Schedule of Property and Equipment (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]
Property and Equipment, gross		$4,725,598	$2,272,445
Less: accumulated depreciation and amortization		-1,022,016	-541,006
Total Property and equipment, net	3,529,265	3,703,582	1,731,439
Construction in Progress
Property, Plant and Equipment [Line Items]
Property and Equipment, gross		308,411	212,189
Analyzers
Property, Plant and Equipment [Line Items]
Property and Equipment, gross		1,421,293	918,940
Computers and office equipment
Property, Plant and Equipment [Line Items]
Property and Equipment, gross		244,454	219,190
Machinery and Equipment
Property, Plant and Equipment [Line Items]
Property and Equipment, gross		910,643	400,154
Leasehold Improvements
Property, Plant and Equipment [Line Items]
Property and Equipment, gross		366,945	326,640
Furniture and Fixtures
Property, Plant and Equipment [Line Items]
Property and Equipment, gross		11,730	6,414
Equipment under capital lease
Property, Plant and Equipment [Line Items]
Property and Equipment, gross		$1,462,122	$188,918

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail) (USD $)	9 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]
Depreciation and amortization of leasehold improvements	$855,484	$549,629	$854,950	$315,655
Leaseholds and Leasehold Improvements
Property, Plant and Equipment [Line Items]
Depreciation and amortization of leasehold improvements			$757,270	$255,092

Schedule_of_Accrued_Liabilitie

Schedule of Accrued Liabilities (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Payables and Accruals [Abstract]
Accrued payroll		$564,740	$441,646
Royalties		105,319
Accrued interest		39,808
Accrued property tax		99,707	50,508
Other		6,240	100
Total accrued liabilities	$858,412	$815,814	$492,254

Commitments_Additional_Informa

Commitments - Additional Information (Detail) (USD $)	0 Months Ended	9 Months Ended	12 Months Ended		0 Months Ended
	Apr. 30, 2014	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012	Jun. 30, 2014
Operating Leased Assets [Line Items]
Sale-leaseback transaction agreement period		4/30/14	10/30/13
Proceeds from sale leaseback	$1,500,000	$1,500,000	$2,500,000
Sale-leaseback transaction renewal period	36 months		36 months
Sale-leaseback transaction monthly payments	64,665		74,875
Sale-leaseback transaction additional renewal period	12 months		12 months
Sale-leaseback transaction lease term	At the end of the lease term, the lease shall automatically renew for twelve additional months at the current monthly rate unless the Company gives written notice 150 days prior to the end of the lease.		At the end of the lease term, the lease shall automatically renew for twelve additional months at the current monthly rate unless the Company gives written notice 150 days prior to the end of the lease.
Sale-leaseback transaction renewal term	Company shall have the opportunity to 1) repurchase the analyzers for a negotiated purchase price, not to exceed forty percent of their original cost; or 2) terminate the lease, return the property and enter into a new lease with new property that replaces the property of the old lease. Both the Company and the lessor shall have the right to reject any terms of option 1 or 2 and if rejected, the 12 month extension shall apply.		The Company shall have the opportunity to 1) repurchase the analyzers for a negotiated purchase price, not to exceed forty percent of their original cost; or 2) terminate the lease, return the property and enter into a new lease with new property that replaces the property of the old lease. Both the Company and the lessor shall have the right to reject any terms of option 1 or 2 and if rejected, the 12 month extension shall apply.
Period of future expense	12 months		12 months
Amounts charged to expense under operating leases			284,941	174,249
Number of molecular diagnostic analyzers	75
Current portion of capital lease obligations	500,000	959,403	506,506	32,543
Minimum
Operating Leased Assets [Line Items]
Capital lease agreements term			3 years
Maximum
Operating Leased Assets [Line Items]
Capital lease agreements term			5 years
Second Financial Advisory Agency Agreement
Operating Leased Assets [Line Items]
Financial advisory fees					15,000
Fee payment upon closure of initial public offering					$100,000
Percentage of total shares agreed to be allocated to the financial advisory company by conversion of warrants issued.					1.00%

Schedule_of_annual_maturities_

Schedule of annual maturities of capital leases (Detail) (USD $)	Sep. 30, 2014	Apr. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Leases [Abstract]
2014			$506,506
2015			613,433
2016			723,938
2017			704,988
Total capital lease commitments			2,548,865
Less: current portion of capital leases	-959,403	-500,000	-506,506	-32,543
Long term portion of capital leases	2,435,625		2,042,359	122,593
Total capital lease commitments			$2,548,865

Schedule_of_operating_lease_co

Schedule of operating lease commitments (Detail) (USD $)	Dec. 31, 2013
Leases [Abstract]
2014	$287,657
2015	97,522
2016	2,397
2017	715
Total operating lease commitments	$388,291

Notes_Payable_Summary_of_Purch

Notes Payable - Summary of Purchased Certain Machinery and Equipment under Two Note Payable Agreements (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Total notes payable	$67,318	$100,331
Less: current portion of notes payable	-48,586	-44,601
Notes payable, net of current portion	18,732	55,730
Note Payable, 15.2% Interest
Debt Instrument [Line Items]
Total notes payable	20,194	29,259
Note Payable, 10.0% Interest
Debt Instrument [Line Items]
Total notes payable	$47,124	$71,072

Notes_Payable_Summary_of_Purch1

Notes Payable - Summary of Purchased Certain Machinery and Equipment under Two Note Payable Agreements (Parenthetical) (Detail) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Note Payable, 15.2% Interest
Debt Instrument [Line Items]
Notes payable, interest rate	15.20%	15.20%
Notes payable, monthly payments	$1,328	$1,328
Notes payable, due date	6-Feb-16	6-Feb-16
Note Payable, 10.0% Interest
Debt Instrument [Line Items]
Notes payable, interest rate	10.00%	10.00%
Notes payable, monthly payments	$3,161	$3,161
Notes payable, due date	1-Jan-16	1-Jan-16

Common_and_Preferred_Stock_Add

Common and Preferred Stock - Additional Information (Detail) (USD $)	9 Months Ended	12 Months Ended		1 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012	Jul. 31, 2014
Class of Stock [Line Items]
Common stock shares, authorized	1,800,000,000	375,000,000	700,000,000
Common stock shares, par value	$0.00	$0.00	$0.00
Common stock shares, issued	161,760	115,510	115,510
Common stock shares, outstanding	161,760	115,510	115,510
Preferred stock, shares issued		0	0
Preferred stock dividends declared per share		$0.01
Dividends of preferred stock in arrears		$5,108,338	$2,574,869
Proceeds from issuance of convertible preferred stock value	6,569,886	1,160,000	170,000
Subscription receivable			3,288,333
Conversion of preferred stock to common stock	1,480,000
Convertible Notes Payable
Class of Stock [Line Items]
Notes qualified for equity financing	5,000,000
Class A Warrant | Convertible Notes Payable
Class of Stock [Line Items]
Warrants issued to purchase comment stock				82,625
Preferred units issued as consideration, warrants price per share				$4.92
Class B Warrant | Convertible Notes Payable
Class of Stock [Line Items]
Warrants issued to purchase comment stock				82,625
Preferred units issued as consideration, warrants price per share				$0.20
Notes Payable To Related Party
Class of Stock [Line Items]
Number of preferred units issued as consideration				4,000,000
Value of preferred units issued as consideration				100,000
Preferred units issued as consideration, price per share				$0.03
Notes Payable To Related Party | Class A Warrant
Class of Stock [Line Items]
Preferred units issued as consideration, warrants price per share				$4.92
Preferred units issued as consideration, warrants				20,000
Notes Payable To Related Party | Class B Warrant
Class of Stock [Line Items]
Preferred units issued as consideration, warrants price per share				$0.20
Preferred units issued as consideration, warrants				20,000
Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock shares, authorized		535,000,000	225,000,000
Preferred stock shares, par value		$0.00	$0.00
Series C Convertible Preferred Stock
Class of Stock [Line Items]
Conversion of preferred stock to common stock, conversion ratio	200	200
Conversion of notes payable to preferred stock		2,442,000
Conversion of notes payable to preferred stock, accrued interest		72,338
Convertible notes, Conversion price per share	$0.02	$0.02
Proceeds from issuance of convertible preferred stock value	366,250	1,160,000
Series C Convertible Preferred Stock | Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock shares, authorized	165,877,435	210,000,000	210,000,000
Preferred stock shares, par value	$0.00	$0.00	$0.00
Preferred stock shares, outstanding	165,877,435	150,989,224	0
Preferred stock liquidation preference per share		$0.05
Stock issued during period upon conversion of debt, value		3,674,338
Preferred stock shares issued	14,888,211	150,989,224
Series D Convertible Preferred Stock
Class of Stock [Line Items]
Conversion of preferred stock to common stock, conversion ratio	200			200
Conversion of notes payable to preferred stock				400,000
Conversion of notes payable to preferred stock, accrued interest				13,129
Convertible notes, Conversion price per share	$0.03			$0.03
Proceeds from issuance of convertible preferred stock value	6,203,636
Gross proceeds from issuance of convertible preferred stock value	7,139,164
Series D Convertible Preferred Stock | Class A Warrant | Convertible Notes Payable
Class of Stock [Line Items]
Warrants issued to purchase comment stock	1,427,832
Preferred units issued as consideration, warrants price per share	$4.92
Warrants granted as part of offering costs	466,436
Series D Convertible Preferred Stock | Class B Warrant | Convertible Notes Payable
Class of Stock [Line Items]
Warrants issued to purchase comment stock	1,427,832
Preferred units issued as consideration, warrants price per share	$0.20
Warrants granted as part of offering costs	251,216
Series D Convertible Preferred Stock | Series D Preferred Stock Warrant
Class of Stock [Line Items]
Warrants granted as part of offering costs	7,200,000
Series D Convertible Preferred Stock | Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock, shares issued	285,566,560
Preferred stock shares, authorized	325,000,000	0
Preferred stock shares, par value	$0.00	$0.00
Preferred stock shares, outstanding	306,091,710	0
Stock issued during period upon conversion of debt, shares				16,525,121
Series A Convertible Preferred Stock
Class of Stock [Line Items]
Conversion of notes payable to preferred stock			6,150,000
Conversion of notes payable to preferred stock, accrued interest			551,856
Convertible notes, Conversion price per share			$0.16
Conversion of stock, shares converted				9,250,000
Conversion of preferred stock to common stock				1,480,000
Conversion of preferred stock to common stock				46,250
Series A Convertible Preferred Stock | Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock shares, authorized	119,987,898	125,000,000	125,000,000
Preferred stock shares, par value	$0.00	$0.00	$0.00
Preferred stock shares, outstanding	107,881,171	117,131,171	117,131,171
Preferred stock liquidation preference per share		$0.32
Stock issued during period upon conversion of debt, shares			41,886,599
Stock issued during period upon conversion of debt, value			6,701,856
Preferred stock, stated value per share				$0.16
Series A Convertible Preferred Stock | Convertible Preferred Stock | Convertible Notes Payable
Class of Stock [Line Items]
Stock issued during period upon conversion of debt, shares			10,599,058
Series B Convertible Preferred Stock
Class of Stock [Line Items]
Conversion of notes payable to preferred stock			5,856,667
Conversion of notes payable to preferred stock, accrued interest			149,456
Convertible notes, Conversion price per share			$0.16
Proceeds from issuance of convertible preferred stock value			170,000
Preferred shares issued, price per share			$0.16
Series B Convertible Preferred Stock | Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock shares, authorized	59,465,350	100,000,000	100,000,000
Preferred stock shares, par value	$0.00	$0.00	$0.00
Preferred stock shares, outstanding	59,465,350	59,465,350	59,465,350
Preferred stock liquidation preference per share		$0.32
Stock issued during period upon conversion of debt, shares			38,632,015
Stock issued during period upon conversion of debt, value			6,176,123
Preferred stock shares issued			20,833,334
Series B Convertible Preferred Stock | Convertible Preferred Stock | Convertible Notes Payable
Class of Stock [Line Items]
Stock issued during period upon conversion of debt, shares			26,160,555
Convertible notes, Conversion price per share			$0.16
Series C-1 Convertible Preferred Stock
Class of Stock [Line Items]
Conversion of notes payable to preferred stock		2,000,000
Conversion of notes payable to preferred stock, accrued interest		67,068
Convertible notes, Conversion price per share		$0.02
Series C-1 Convertible Preferred Stock | Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock shares, authorized	84,027,175	100,000,000	100,000,000
Preferred stock shares, par value	$0.00	$0.00	$0.00
Preferred stock shares, outstanding	84,027,175	84,027,175	0
Preferred stock liquidation preference per share		$0.05
Stock issued during period upon conversion of debt, value		$2,067,068
Preferred stock shares issued		84,027,174

Warrants_Additional_Informatio

Warrants - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended	9 Months Ended	0 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Nov. 25, 2013	Nov. 14, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Class of Warrant or Right [Line Items]
Fair value of warrant expensed	$25,061	$13,900,400	$13,900,400
Warrant
Class of Warrant or Right [Line Items]
Fair value of liability	$0	$0	$0
Common Stock Warrants
Class of Warrant or Right [Line Items]
Warrants outstanding	4,178,782	4,178,782	4,178,782			274,420	174,420	174,420
Warrants granted			3,904,362			100,000	0
Preferred units issued as consideration, warrants price per share	$2.98	$2.98	$2.98	$2	$2	$7.08	$10	$10
Warrants expiration period				7 years	7 years
Preferred A Stock Warrants
Class of Warrant or Right [Line Items]
Warrants outstanding	2,231,727	2,231,727	2,231,727			2,231,727	2,231,727	2,231,727
Warrants granted			0			0	0
Preferred units issued as consideration, warrants price per share	$0.16	$0.16	$0.16			$0.16	$0.16	$0.16
Preferred D Stock Warrants
Class of Warrant or Right [Line Items]
Warrants outstanding	7,200,000	7,200,000	7,200,000			0
Warrants granted			7,200,000
Preferred units issued as consideration, warrants price per share	$0.03	$0.03	$0.03			$0
Class A And Class B Warrants
Class of Warrant or Right [Line Items]
Warrants granted			2,855,664
Class A And Class B Warrants | Minimum
Class of Warrant or Right [Line Items]
Preferred units issued as consideration, warrants price per share	$0.20	$0.20	$0.20
Warrants expire period			2021-04
Class A And Class B Warrants | Maximum
Class of Warrant or Right [Line Items]
Preferred units issued as consideration, warrants price per share	$4.92	$4.92	$4.92
Warrants expire period			2021-07
Warrants Issued Convertible Notes Payable
Class of Warrant or Right [Line Items]
Common stock warrants granted with nominal value			1,048,698
Warrants Issued Convertible Notes Payable | Minimum
Class of Warrant or Right [Line Items]
Preferred units issued as consideration, warrants price per share	$0.20	$0.20	$0.20
Warrants expire period			2021-02
Warrants Issued Convertible Notes Payable | Maximum
Class of Warrant or Right [Line Items]
Preferred units issued as consideration, warrants price per share	$4.92	$4.92	$4.92
Warrants expire period			2021-07

Warrants_Common_Stock_Warrants

Warrants - Common Stock Warrants Activity (Detail) (Common Stock Warrants, USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Nov. 25, 2013	Nov. 14, 2013
Class of Warrant or Right [Line Items]
Warrants, Beginning Balance	274,420	174,420	174,420
Warrants granted	3,904,362	100,000	0
Warrants Exercised	0	0	0
Warrants Expired	0	0	0
Warrants, Ending Balance	4,178,782	274,420	174,420	174,420
Weighted Average Exercise Price, Warrants Outstanding Beginning Balance	$7.08	$10	$10		$2	$2
Weighted Average Exercise Price,Granted	$2.69	$2
Weighted Average Exercise Price, Exercised	$0	$0	$0
Weighted Average Exercise Price, Expired	$0	$0	$0
Weighted Average Exercise Price, Warrants Outstanding Ending Balance	$2.98	$7.08	$10	$10	$2	$2
Warrants Weighted Average Remainder Contractual Terms Granted	6 years 8 months 12 days	7 years	0 years
Weighted Average Remainder Contractual Term in Years, Exercised	0 years	0 years	0 years
Weighted Average Remainder Contractual Term in Years, Expired	0 years	0 years	0 years
Weighted Average Remainder Contractual Term in Years, Warrants Outstanding	6 years 2 months 12 days	4 years 2 months 12 days	3 years 9 months 18 days	4 years 9 months 18 days
Scenario, Previously Reported
Class of Warrant or Right [Line Items]
Weighted Average Exercise Price, Warrants Outstanding Ending Balance		$8

Warrants_Preferred_A_Stock_War

Warrants - Preferred A Stock Warrants Activity (Detail) (Preferred A Stock Warrants, USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Preferred A Stock Warrants
Class of Warrant or Right [Line Items]
Warrants, Beginning Balance	2,231,727	2,231,727	2,231,727
Warrants granted	0	0	0
Warrants Exercised	0	0	0
Warrants Expired	0	0	0
Warrants, Ending Balance	2,231,727	2,231,727	2,231,727	2,231,727
Weighted Average Exercise Price, Warrants Outstanding Beginning Balance	$0.16	$0.16	$0.16
Weighted Average Exercise Price,Granted	$0	$0	$0
Weighted Average Exercise Price, Exercised	$0	$0	$0
Weighted Average Exercise Price, Expired	$0	$0	$0
Weighted Average Exercise Price, Warrants Outstanding Ending Balance	$0.16	$0.16	$0.16	$0.16
Warrants Weighted Average Remainder Contractual Terms Granted	0 years	0 years	0 years
Weighted Average Remainder Contractual Term in Years, Exercised	0 years	0 years	0 years
Weighted Average Remainder Contractual Term in Years, Expired	0 years	0 years	0 years
Warrants outstanding as of September 30, 2014	3 years 1 month 6 days	3 years 1 month 6 days	4 years 1 month 6 days	5 years 1 month 6 days

Employee_Stock_Options_Additio

Employee Stock Options - Additional Information (Detail) (USD $)	9 Months Ended		12 Months Ended		0 Months Ended	1 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Oct. 30, 2013	Sep. 30, 2014	Dec. 31, 2011
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of stock options, outstanding	578,750		115,750	110,750		578,750	110,750
Options, Granted	586,250		5,000
Weighted Average Exercise Price, Granted	$2.20		$2
Unrecognized compensation cost related to stock option	$154	$47,591	$19,818	$130,909		$154
Remaining vesting period of stock option	15 days	5 months 5 days	3 months 18 days	1 year 2 months 12 days
Aggregate intrinsic value of outstanding and vested stock options	148,560		0			148,560
Exercise price	$0
Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of stock options, outstanding	578,750		115,750	110,750		578,750
Stock options, vesting period	4 years		4 years	4 years
Stock options, maturity period	10 years		10 years	10 years
Options, Granted					5,000
Weighted Average Exercise Price, Granted					$2
Number of stock based compensation plans	2
Number of stock options, outstanding						103,250
Exercise price						$3.50
Incremental fair value						$223,031

Employee_Stock_Options_Summary

Employee Stock Options - Summary of Stock Option Activity (Detail) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding, Beginning balance	115,750	110,750	110,750
Options, Granted	586,250	5,000
Options, Exercised	0	0	0
Options, Cancelled	123,250
Options outstanding, Ending Balance	578,750	115,750	110,750	110,750
Weighted Average Exercise Price Outstanding, Beginning Balance	$30.70	$32	$32
Weighted Average Exercise Price, Granted	$2.20	$2
Weighted Average Exercise Price, Exercised	$0
Weighted Average Exercise Price, Cancelled	$27.13
Weighted Average Exercise Price, Outstanding Ending Balance	$2.65	$30.70	$32	$32
Weighted Average Remainder Contractual Terms Outstanding Beginning	8 years 8 months 12 days	6 years 3 months 18 days	7 years 2 months 12 days	8 years 2 months 12 days
Weighted Average Remaining Contractual Term in Years, Granted	10 years	9 years 9 months 18 days
Weighted Average Remaining Contractual Term in Years, Exercised	0 years
Weighted Average Remaining Contractual Term in Years, Cancelled	6 years 1 month 6 days
Scenario, Previously Reported
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted Average Exercise Price, Outstanding Ending Balance		$30

Employee_Stock_Options_Summary1

Employee Stock Options - Summary of Stock Options Outstanding and Exercisable (Detail) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number of Options Outstanding	578,750	115,750	110,750	110,750
Weighted Average Remainder Contractual Terms Outstanding Beginning	8 years 8 months 12 days	6 years 3 months 18 days	7 years 2 months 12 days	8 years 2 months 12 days
Options Outstanding, Exercise Price	$2.65	$30	$32
Number of Options Exercisable	110,667	106,570	78,049
Options Exercisable, Exercise Price	$5.43	$32	$32

Employee_Stock_Options_Schedul

Employee Stock Options - Schedule of Equity-Based Compensation Expenses (Detail) (USD $)	9 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock based compensation expense	$242,696	$83,318	$111,091	$111,091
Income tax benefit recognized related to stock-based compensation			0	0
Income tax benefit realized from the exercising and vesting of options			$0	$0

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)	12 Months Ended		0 Months Ended		12 Months Ended
	Dec. 31, 2012	Dec. 31, 2013	Nov. 25, 2013	Nov. 14, 2013	Dec. 31, 2011	Sep. 30, 2014
Related Party Transaction [Line Items]
Stock subscription receivable	$3,288,333
Series B Convertible Preferred Stock
Related Party Transaction [Line Items]
Convertible debt, conversion price	$0.16
Convertible debt, amount converted	5,856,667
Share price, new issue	$0.16
Series B Convertible Preferred Stock | Convertible Preferred Stock
Related Party Transaction [Line Items]
Shares issued upon conversion of debt	38,632,015
Series A Convertible Preferred Stock
Related Party Transaction [Line Items]
Convertible debt, conversion price	$0.16
Convertible debt, amount converted	6,150,000
Series A Convertible Preferred Stock | Convertible Preferred Stock
Related Party Transaction [Line Items]
Shares issued upon conversion of debt	41,886,599
Sale Leaseback Obligations
Related Party Transaction [Line Items]
Letter of credit		3,000,000
Sale Leaseback Obligations | Letter of Credit
Related Party Transaction [Line Items]
Line of credit, amount drawn		0
Convertible Notes Payable
Related Party Transaction [Line Items]
Interest rate on notes	8.00%	8.00%
Convertible Notes Payable | Series C and Series C-1 preferred stock | Convertible Preferred Stock
Related Party Transaction [Line Items]
Shares issued upon conversion of debt		116,565,430
Convertible debt, conversion price		$0.02
Convertible Notes Payable | Series B Convertible Preferred Stock | Convertible Preferred Stock
Related Party Transaction [Line Items]
Shares issued upon conversion of debt	26,160,555
Convertible debt, conversion price	$0.16
Convertible Notes Payable | Series B Convertible Preferred Stock | Convertible Preferred Stock | Accrued Interest
Related Party Transaction [Line Items]
Convertible debt, amount converted	92,355
Convertible Notes Payable | Series A Convertible Preferred Stock | Convertible Preferred Stock
Related Party Transaction [Line Items]
Shares issued upon conversion of debt	10,599,058
Convertible Notes Payable | Series A Convertible Preferred Stock | Convertible Preferred Stock | Convertible promissory notes issued in 2011
Related Party Transaction [Line Items]
Shares issued upon conversion of debt	17,324,812
Convertible debt, conversion price	$0.16
Convertible Notes Payable | Series A Convertible Preferred Stock | Convertible Preferred Stock | Accrued Interest
Related Party Transaction [Line Items]
Convertible debt, amount converted	95,848
Convertible Notes Payable | Series A Convertible Preferred Stock | Convertible Preferred Stock | Accrued Interest | Convertible promissory notes issued in 2011
Related Party Transaction [Line Items]
Convertible debt, amount converted	271,970
Common Stock Warrants
Related Party Transaction [Line Items]
Warrant exercise price	$10	$7.08	$2	$2	$10	$2.98
Warrant expiration period			7 years	7 years
SSA Ventures, LLC | Series B Convertible Preferred Stock | Convertible Preferred Stock
Related Party Transaction [Line Items]
Preferred stock, shares issued	10,416,667
Stock subscription receivable	1,666,667
Share price, new issue	$0.16
SSA Ventures, LLC | Convertible Notes Payable
Related Party Transaction [Line Items]
Proceeds from issuance of convertible promissory notes		571,000
SSA Ventures, LLC | Convertible Notes Payable | Convertible Note 1
Related Party Transaction [Line Items]
Proceeds from issuance of convertible promissory notes	1,213,333
SSA Ventures, LLC | Convertible Notes Payable | Convertible Note 2
Related Party Transaction [Line Items]
Proceeds from issuance of convertible promissory notes	800,000				1,250,000
SBS Charitable Remainder Trust | Convertible Notes Payable
Related Party Transaction [Line Items]
Proceeds from issuance of convertible promissory notes		2,000,000
Bourne Spafford Charitable Trust | Convertible Notes Payable
Related Party Transaction [Line Items]
Proceeds from issuance of convertible promissory notes		200,000
Spring Forth Investments and the Bourne Spafford Charitable Trust | Convertible Notes Payable
Related Party Transaction [Line Items]
Proceeds from issuance of convertible promissory notes	2,880,000
Spring Forth Investments | Convertible Notes Payable
Related Party Transaction [Line Items]
Proceeds from issuance of convertible promissory notes	$800,000				$1,250,000
Ryan Ashton, Chief Executive Officer | Common Stock Warrants
Related Party Transaction [Line Items]
Warrants issued			50,000
David Spafford, a director | Common Stock Warrants
Related Party Transaction [Line Items]
Warrants issued			50,000

Income_Tax_Expense_Detail

Income Tax Expense (Detail) (USD $)	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Current
Federal			$0	$0
State and Local			1,250	100
Current income tax expense benefit			1,250	100
Deferred
Federal			0	0
State and Local			0	0
Deferred income tax expense benefit			0	0
Income tax expense benefit net	($822)	$5,297	$1,250	$100

Components_of_Deferred_Tax_Ass

Components of Deferred Tax Assets (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current deferred tax assets:
Allowance for doubtful accounts	$2,035
Accrued vacation	131,302	86,052
Accrued personal property tax	37,012	18,823
Total current deferred tax assets	170,349	104,875
Non-current deferred tax assets
Net operating losses	13,674,825	10,243,639
Depreciation and amortization	15,935	53,509
Other	171	171
Total non-current deferred tax assets	13,690,931	10,297,319
Total deferred tax assets	13,861,280	10,402,194
Less: Valuation allowance	-13,861,280	-10,402,194
Net deferred tax assets	$0	$0

Reconciliation_of_Reported_Amo

Reconciliation of Reported Amount of Income Tax Expense (Detail) (USD $)	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Benefit for income taxes computed at federal statutory rate			$3,672,568	$1,910,905
State income taxes, net of federal tax benefit			248,065	187,604
Non-deductible expenses			-7,473	-6,896
Increase in valuation allowance			-3,914,410	-2,091,713
Provision for income taxes	$822	($5,297)	($1,250)	($100)
Effective tax rate			-0.03%	-0.01%

Income_Tax_Additional_Informat

Income Tax - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Taxes [Line Items]
Unrecognized tax benefits	$0	$0
Unrecognized tax benefits income tax penalties and interest recognized	0	0
Unrecognized tax benefits income tax penalties and interest accrued	0	0
Federal
Income Taxes [Line Items]
Net operating loss carry forwards	37,800,000	28,300,000
Net tax operating losses, expiration	Expire in varying amounts during the tax years 2023 through 2033.
Federal | Minimum
Income Taxes [Line Items]
Tax years open to examination	2010
Federal | Maximum
Income Taxes [Line Items]
Tax years open to examination	2013
State
Income Taxes [Line Items]
Net operating loss carry forwards	$26,300,000	$18,600,000
Net tax operating losses, expiration	Expire in varying years from 2023 to 2033.

Schedule_of_Domestic_and_Inter

Schedule of Domestic and International Customers Products Sales (Detail) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Schedule Of Geographical Information [Line Items]
Total sales	$409,390	$223,470	$1,160,971	$464,861	$760,646	$38,667
Domestic (U.S.)
Schedule Of Geographical Information [Line Items]
Total sales					736,215	27,319
International
Schedule Of Geographical Information [Line Items]
Total sales					$24,431	$11,348

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (USD $)

0 Months Ended

9 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

2 Months Ended

1 Months Ended

Apr. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Dec. 31, 2012

Oct. 30, 2013

Jun. 30, 2014

Jul. 31, 2014

Oct. 08, 2014

Apr. 30, 2014

Oct. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Jun. 30, 2014

Feb. 18, 2014

Agreement

Subsequent Event [Line Items]

Proceeds from issuance of convertible preferred stock value

$6,569,886

$1,160,000

$170,000

Exercise price of options granted

$2.20

$2

Sale-leaseback transaction agreement period

4/30/14

10/30/13

Number of molecular diagnostic analyzers

75

75

Proceeds from sale leaseback

1,500,000

1,500,000

2,500,000

Sale-leaseback transaction monthly payments

64,665

74,875

Common stock, shares authorized

1,800,000,000

375,000,000

700,000,000

Employee Stock Option

Subsequent Event [Line Items]

Exercise price of options granted

$2

Options granted, vesting period

4 years

4 years

4 years

Stock options, maturity period

10 years

10 years

10 years

Convertible Notes Payable

Subsequent Event [Line Items]

Notes qualified for equity financing

5,000,000

Notes payable, interest rate

8.00%

8.00%

Second Financial Advisory Agency Agreement

Subsequent Event [Line Items]

Financial advisory fees

15,000

Fee payment upon closure of initial public offering

100,000

Percentage of total shares agreed to be allocated to the financial advisory company by conversion of warrants issued

1.00%

1.00%

Class A Warrant | Convertible Notes Payable

Subsequent Event [Line Items]

Warrants issued

82,625

Preferred units issued as consideration, warrants price per share

$4.92

Class B Warrant | Convertible Notes Payable

Subsequent Event [Line Items]

Warrants issued

82,625

Preferred units issued as consideration, warrants price per share

$0.20

Series C Convertible Preferred Stock

Subsequent Event [Line Items]

Proceeds from issuance of convertible preferred stock value

366,250

1,160,000

Convertible notes, Conversion price per share

$0.02

$0.02

Conversion of preferred stock to common stock, conversion ratio

200

200

Series C Convertible Preferred Stock | Convertible Preferred Stock

Subsequent Event [Line Items]

Number of preferred stock units sold

14,888,211

150,989,224

Series D Convertible Preferred Stock

Subsequent Event [Line Items]

Proceeds from issuance of convertible preferred stock value

6,203,636

Convertible notes, Conversion price per share

$0.03

$0.03

Conversion of preferred stock to common stock, conversion ratio

200

200

Gross proceeds from issuance of convertible preferred stock value

7,139,164

Series D Convertible Preferred Stock | Class A Warrant | Convertible Notes Payable

Subsequent Event [Line Items]

Warrants issued

1,427,832

Preferred units issued as consideration, warrants price per share

$4.92

Series D Convertible Preferred Stock | Class B Warrant | Convertible Notes Payable

Subsequent Event [Line Items]

Warrants issued

1,427,832

Preferred units issued as consideration, warrants price per share

$0.20

Subsequent Event

Subsequent Event [Line Items]

Preferred stock, dividend rate per annum

8.00%

Sale-leaseback transaction agreement period

4/30/14

Number of molecular diagnostic analyzers

75

75

Proceeds from sale leaseback

1,500,000

Sale-leaseback transaction, equipment leases repaid

125,751

Sale-leaseback transaction monthly payments

64,665

Sale-leaseback transaction agreement, lease period

2 years

Warrants exercised by underwriter

172,500

Initial public offering trade date

9-Sep-14

Proceeds from Issuance Initial Public Offering

6,400,000

Converted preferred stock units

3,616,702

Preferred stock warrants converted to common stock warrants

47,158

Common stock, shares authorized

50,000,000

Preferred stock, shares authorized

5,000,000

Subsequent Event | Employee Stock Option

Subsequent Event [Line Items]

Options granted

393,000

Exercise price of options granted

2

Options granted, vesting period

4 years

Stock options, maturity period

10 years

Subsequent Event | 2014 OmniBus

Subsequent Event [Line Items]

Options granted

52,500

Exercise price of options granted

$7

Options granted, vesting period

3 years

Options granted for each director

17,500

Options granted, expiration date

2024

Subsequent Event | Omnibus Incentive Plan | Chief Financial Officer

Subsequent Event [Line Items]

Options granted

50,784

Exercise price of options granted

$7

Options granted, expiration date

2024

Subsequent Event | Omnibus Incentive Plan | Chief Financial Officer | Vest immediately

Subsequent Event [Line Items]

Options granted, vesting percentage

25.00%

Subsequent Event | Omnibus Incentive Plan | Chief Financial Officer | Vest over a three year period

Subsequent Event [Line Items]

Options granted, vesting percentage

75.00%

Subsequent Event | Convertible Notes Payable

Subsequent Event [Line Items]

Convertible notes issued

400,000

Notes payable, due date

10-Mar-15

Notes qualified for equity financing

5,000,000

Notes payable, interest rate

8.00%

8.00%

Subsequent Event | Notes Payable

Subsequent Event [Line Items]

Short terms notes payable, interest rate

0

Short terms notes payable, due date

1-May-14

Payment for retirement of short term related party notes payable

390,000

Subsequent Event | First Financial Advisory Agency Agreement

Subsequent Event [Line Items]

Financial advisory fees

15,000

Subsequent Event | Second Financial Advisory Agency Agreement

Subsequent Event [Line Items]

Financial advisory fees

15,000

Fee to be paid upon the filling of S-1 with SEC

50,000

50,000

Fee payment upon closure of initial public offering

100,000

Percentage of total shares agreed to be allocated to the financial advisory company by conversion of warrants issued

1.00%

1.00%

Subsequent Event | Ryan Ashton, Chief Executive Officer | Notes Payable

Subsequent Event [Line Items]

Short terms notes payable issued

350,000

Payment for retirement of short term related party notes payable

350,000

Subsequent Event | David Spafford, a director | Notes Payable

Subsequent Event [Line Items]

Short terms notes payable issued

40,000

Payment for retirement of short term related party notes payable

40,000

Subsequent Event | Common Stock

Subsequent Event [Line Items]

Warrants issued

50,000

50,000

Preferred units issued as consideration, warrants price per share

$2

2

$2

$2

Warrants expiration period

7 years

7 years

Subsequent Event | Common Stock | Warrant

Subsequent Event [Line Items]

Share issued for consulting services

9,278

Subsequent Event | Series D Units

Subsequent Event [Line Items]

Number of preferred stock units sold

89,400,000

Proceeds from issuance of convertible preferred stock value

2,044,477

Gross proceeds from issuance of convertible preferred stock value

2,235,000

Subsequent Event | Series D Units | First Financial Advisory Agency Agreement | Minimum

Subsequent Event [Line Items]

Number of preferred stock units sold

1,800,000

Subsequent Event | Series D Units | First Financial Advisory Agency Agreement | Maximum

Subsequent Event [Line Items]

Number of preferred stock units sold

7,200,000

Subsequent Event | Class A Warrant | Series D Units

Subsequent Event [Line Items]

Warrants issued

447,000

447,000

Preferred units issued as consideration, warrants price per share

$4.92

4.92

Subsequent Event | Class A Warrant | Series D Units | First Financial Advisory Agency Agreement | Minimum

Subsequent Event [Line Items]

Warrants issued

9,000

9,000

Subsequent Event | Class A Warrant | Series D Units | First Financial Advisory Agency Agreement | Maximum

Subsequent Event [Line Items]

Warrants issued

36,000

36,000

Subsequent Event | Class B Warrant

Subsequent Event [Line Items]

Warrants Exercised

150,000

Proceeds from exercise of warrants

30,000

Purchase price of common stock

$0.20

Subsequent Event | Class B Warrant | Series D Units

Subsequent Event [Line Items]

Warrants issued

447,000

447,000

Preferred units issued as consideration, warrants price per share

$0.20

0.2

Subsequent Event | Class B Warrant | Series D Units | First Financial Advisory Agency Agreement | Minimum

Subsequent Event [Line Items]

Warrants issued

9,000

9,000

Subsequent Event | Class B Warrant | Series D Units | First Financial Advisory Agency Agreement | Maximum

Subsequent Event [Line Items]

Warrants issued

36,000

36,000

Subsequent Event | Series C Convertible Preferred Stock | Convertible Preferred Stock

Subsequent Event [Line Items]

Number of preferred stock units sold

14,888,211

Proceeds from issuance of convertible preferred stock value

$366,250

Preferred shares issued, price per share

$0.02

Conversion of preferred stock to common stock, conversion ratio

200

Subsequent Event | Series C Convertible Preferred Stock | Convertible Preferred Stock | Convertible Notes Payable

Subsequent Event [Line Items]

Convertible notes, Conversion price per share

$0.02

$0.02

Subsequent Event | Series D Convertible Preferred Stock

Subsequent Event [Line Items]

Conversion of preferred stock to common stock, conversion ratio

200

Subsequent Event | Series D Convertible Preferred Stock | Series D Units

Subsequent Event [Line Items]

Number of preferred stock units sold

89,400,000

Subsequent Event | Series D Convertible Preferred Stock | Series D Units | First Financial Advisory Agency Agreement | Minimum

Subsequent Event [Line Items]

Number of preferred stock units sold

1,800,000

Subsequent Event | Series D Convertible Preferred Stock | Series D Units | First Financial Advisory Agency Agreement | Maximum

Subsequent Event [Line Items]

Number of preferred stock units sold

7,200,000

Subsequent Event | IPO

Subsequent Event [Line Items]

Number of preferred stock units sold

1,150,000

Subsequent Event | IPO | Class A Warrant

Subsequent Event [Line Items]

Preferred units issued as consideration, warrants price per share

$7

Warrants issued during period

1,150,000

Subsequent Event | Underwriters Warrants

Subsequent Event [Line Items]

Preferred units issued as consideration, warrants price per share

$8.75

Exercisable warrants of common stock

57,500

Investment Warrants Expiration Date

31-Oct-19

Notes_Payable_Related_Party_Ad

Notes Payable - Related Party - Additional Information (Detail) (USD $)	1 Months Ended
	Jul. 31, 2014	Sep. 30, 2014
Related Party Transaction [Line Items]
Notes payable - related party, discount		$83,333
Notes Payable To Related Party
Related Party Transaction [Line Items]
Note agreement amount	500,000
Notes payable, interest rate	20.00%
Note maturity date description	The Company may extend the due date of the note to July 18, 2016 by giving notice no later than April 18, 2015
Note extension fee amount	10,000
Notes, maturity date	18-Jul-15
Prepaid interest	25,000
Number of preferred units issued as consideration	4,000,000
Value of preferred units issued as consideration	100,000
Preferred units issued as consideration, series D preferred shares	4,000,000
Preferred units issued as consideration, price per share	$0.03
Notes payable - related party, discount		$83,333
Notes Payable To Related Party | Class A Warrant
Related Party Transaction [Line Items]
Preferred units issued as consideration, warrants	20,000
Preferred units issued as consideration, warrants price per share	$4.92
Notes Payable To Related Party | Class B Warrant
Related Party Transaction [Line Items]
Preferred units issued as consideration, warrants	20,000
Preferred units issued as consideration, warrants price per share	$0.20

Warrants_Summary_of_Change_in_

Warrants - Summary of Change in the Value of the Warrant Liability (Detail) (USD $)	1 Months Ended	3 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014
Warrants and Rights Note Disclosure [Abstract]
Balance beginning of period			$0
Issuance of warrants			0
Change in fair value measurement	25,061	13,900,400	13,900,400
Balance at end of period	$13,900,400	$13,900,400	$13,900,400

Warrants_BlackScholesMerton_Op

Warrants - Black-Scholes-Merton Option Pricing Model (Detail) (USD $)	9 Months Ended
	Sep. 30, 2014
Warrant
Class of Warrant or Right [Line Items]
Fair Market Value	$4.94
Exercise Price	$10
Risk Free Rate	0.61%
Dividend Yield	0.00%
Expected Volatility	37.23%
Contractual Term	1 year 11 months 19 days
Class A And Class B Warrants
Class of Warrant or Right [Line Items]
Fair Market Value	$4.94
Risk Free Rate	2.20%
Dividend Yield	0.00%
Expected Volatility	50.27%
Contractual Term	6 years 9 months
Class A And Class B Warrants | Minimum
Class of Warrant or Right [Line Items]
Exercise Price	$0.20
Class A And Class B Warrants | Maximum
Class of Warrant or Right [Line Items]
Exercise Price	$4.92

Warrants_Preferred_D_Stock_War

Warrants - Preferred D Stock Warrants Activity (Detail) (Preferred D Stock Warrants, USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Preferred D Stock Warrants
Class of Warrant or Right [Line Items]
Warrants, Beginning Balance	0
Warrants granted	7,200,000
Warrants Exercised	0
Warrants Expired	0
Warrants, Ending Balance	7,200,000	0
Weighted Average Exercise Price, Warrants Outstanding Beginning Balance	$0
Weighted Average Exercise Price,Granted	$0.03
Weighted Average Exercise Price, Exercised	$0
Weighted Average Exercise Price, Expired	$0
Weighted Average Exercise Price, Warrants Outstanding Ending Balance	$0.03	$0
Warrants Weighted Average Remainder Contractual Terms Granted	6 years 9 months 18 days
Weighted Average Remainder Contractual Term in Years, Exercised	0 years
Weighted Average Remainder Contractual Term in Years, Expired	0 years
Warrants outstanding as of September 30, 2014	6 years 9 months 18 days	0 years

Employee_Stock_Options_Schedul1

Employee Stock Options - Schedule of Assumptions Used in Calculation of Fair Value of the Options Exchanged (Detail) (Employee Stock Option, USD $)	9 Months Ended
	Sep. 30, 2014
Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair Market Value	$4.94
Exercise Price	$3.50
Risk Free Rate	1.06%
Dividend Yield	0.00%
Expected Volatility	46.31%
Contractual Term	2 years 8 months 27 days